Identification

Name
Iloperidone
Accession Number
DB04946
Type
Small Molecule
Groups
Approved
Description

Iloperidone is an atypical antipsychotic for the treatment of schizophrenia symptoms. Hoechst Marion Roussel Inc. made initial inquiries into the drug; however, in May 1996, they discontinued research, and in June 1997 gave research rights to Titan Pharmaceuticals. Titan then handed over worldwide development, manufacturing and marketing rights to Novartis in August 1998. On June 9, 2004, Titan Pharmaceuticals announced that the Phase III development rights have been acquired by Vanda Pharmaceuticals. FDA approved on May 9, 2009.

Structure
Thumb
Synonyms
  • 1-[4-[3-[4-(6-Fluoro-1,2-benzisoxazol-3-yl)-1- piperidinyl]propoxy]-3-methoxyphenyl]ethanone
  • 4'-(3-(4-(6-Fluoro-1,2-benzisoxazol-3-yl)piperidino)propoxy)-3'-methoxyacetophenone
  • Fanapta
  • Iloperidona
  • Iloperidonum
  • Zomaril
External IDs
HP 873 / HP-873
Product Images
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
FanaptTablet6 mg/1OralNovartis2009-10-012017-12-22Us00078 0598 20 nlmimage10 e13af0a7
FanaptTablet4 mg/1OralAvera Mc Kennan Hospital2015-06-02Not applicableUs
FanaptTablet4 mg/1OralVanda Pharmaceuticals2015-12-15Not applicableUs
FanaptTablet2 mg/1OralVanda Pharmaceuticals2016-08-01Not applicableUs
FanaptKitOralVanda Pharmaceuticals2015-12-01Not applicableUs
FanaptTablet10 mg/1OralNovartis2009-10-012017-12-22Us
FanaptTablet1 mg/1OralNovartis2009-10-012017-12-22Us
FanaptTablet12 mg/1OralVanda Pharmaceuticals2016-10-15Not applicableUs
FanaptTablet1 mg/1OralVanda Pharmaceuticals2016-05-01Not applicableUs
FanaptKitOralNovartis2009-10-012017-12-22Us
Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
IloperidoneTablet1 mg/1OralMylan Pharmaceuticals2017-03-20Not applicableUs
IloperidoneTablet10 mg/1OralMylan Pharmaceuticals2017-03-20Not applicableUs
IloperidoneTablet4 mg/1OralMylan Pharmaceuticals2017-03-20Not applicableUs
IloperidoneTablet8 mg/1OralMylan Pharmaceuticals2017-03-20Not applicableUs
IloperidoneTablet2 mg/1OralMylan Pharmaceuticals2017-03-20Not applicableUs
IloperidoneTablet12 mg/1OralMylan Pharmaceuticals2017-03-20Not applicableUs
IloperidoneTablet6 mg/1OralMylan Pharmaceuticals2017-03-20Not applicableUs
International/Other Brands
Fanapt / Fiapta / Zomaril
Categories
UNII
VPO7KJ050N
CAS number
133454-47-4
Weight
Average: 426.4806
Monoisotopic: 426.195485567
Chemical Formula
C24H27FN2O4
InChI Key
XMXHEBAFVSFQEX-UHFFFAOYSA-N
InChI
InChI=1S/C24H27FN2O4/c1-16(28)18-4-7-21(23(14-18)29-2)30-13-3-10-27-11-8-17(9-12-27)24-20-6-5-19(25)15-22(20)31-26-24/h4-7,14-15,17H,3,8-13H2,1-2H3
IUPAC Name
1-(4-{3-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]propoxy}-3-methoxyphenyl)ethan-1-one
SMILES
COC1=C(OCCCN2CCC(CC2)C2=NOC3=C2C=CC(F)=C3)C=CC(=C1)C(C)=O

Pharmacology

Indication

Treatment of acute schizophrenia.

Associated Conditions
Pharmacodynamics

Iloperidone shows high affinity and maximal receptor occupancy for dopamine D2 receptors in the caudate nucleus and putamen of the brains of schizophrenic patients. The improvement in cognition is attributed to iloperidone's high affinity for α adrenergic receptors. Iloperidone also binds with high affinity to serotonin 5-HT2a and dopamine 3 receptors. Iloperidone binds with moderate affinity to dopamine D4, serotonin 5-HT6 and 5-HT7, and norepinephrine NEα1 receptors. Furthermore, iloperidone binds with weak affinity to serotonin 5-HT1A, dopamine D1, and histamine H1 receptors.

Mechanism of action

Iloperidone is a dopamine D2 and 5-HT2A receptor antagonist and acts as a neuroleptic agent.

TargetActionsOrganism
A5-hydroxytryptamine receptor 2A
antagonist
Human
AD(2) dopamine receptor
antagonist
Human
UD(1A) dopamine receptor
antagonist
Human
UD(3) dopamine receptor
antagonist
Human
UD(4) dopamine receptor
antagonist
Human
U5-hydroxytryptamine receptor 1A
antagonist
Human
U5-hydroxytryptamine receptor 6
antagonist
Human
U5-hydroxytryptamine receptor 7
antagonist
Human
UAlpha-1A adrenergic receptor
antagonist
Human
UHistamine H1 receptor
antagonist
Human
UAlpha-2C adrenergic receptor
antagonist
Human
Absorption

Well absorbed from the GI tract and Cmax is reached within 2-4 hours. Steady-state concentration is achieved in 3-4 days post-administration of iloperidone. Relative bioavailability of the tablet formulation compared to oral solution is 96%. Accumulation occurs in a predictable fashion.

Volume of distribution

Apparent Vd = 1340-2800 L

Protein binding

95% of iloperidone is bound to protein. Percent bound is not altered by renal or hepatic impairment or combination therapy with ketoconazole.

Metabolism

Iloperidone is hepatically metabolized by cytochrome enzymes which mediates O-dealkylation (CYP3A4), hydroxylation (CYP2D6), and decarboxylation/reduction processes. Metabolites formed are P89, P95, and P88. The minor metabolite is P89, whereas P95 and P88 are the major ones. The affinity of the iloperidone metabolite P88 is generally equal or less than that of the parent compound. In contrast, the metabolite P95 only shows affinity for 5-HT2A (Ki value of 3.91) and the NEα1A, NEα1B, NEα1D, and NEα2C receptors (Ki values of 4.7, 2.7, 8.8 and 4.7 nM respectively).

Route of elimination

Renal (in which <1% of iloperidone is excreted unchanged).

Half life

The observed mean elimination half-lives for iloperidone, P88 and P95 in CYP2D6 extensive metabolizers (EM) are 18, 26 and 23 hours, respectively, and in poor metabolizers (PM) are 33, 37 and 31 hours, respectively.

Clearance

Apparent clearance (clearance/bioavilability) = 47-102 L/h.

Toxicity

Commonly observed adverse reactions (incidence ≥5% and two-fold greater than placebo) were: dizziness, dry mouth, fatigue, nasal congestion, orthostatic hypotension, somnolence, tachycardia, and weight increased.

Affected organisms
  • Humans and other mammals
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Interacting Gene/EnzymeAllele nameGenotype(s)Defining Change(s)Type(s)DescriptionDetails
Cytochrome P450 2D6CYP2D6*3Not AvailableC alleleEffect InferredPoor drug metabolizer, lower dose requirement.Details
Cytochrome P450 2D6CYP2D6*4Not AvailableC alleleEffect InferredPoor drug metabolizer, lower dose requirement.Details
Cytochrome P450 2D6CYP2D6*5Not AvailableWhole-gene deletionEffect InferredPoor drug metabolizer, lower dose requirement.Details
Cytochrome P450 2D6CYP2D6*6Not Available1707delTEffect InferredPoor drug metabolizer, lower dose requirement.Details
Cytochrome P450 2D6CYP2D6*7Not Available2935A>CEffect InferredPoor drug metabolizer, lower dose requirement.Details
Cytochrome P450 2D6CYP2D6*8Not Available1758G>TEffect InferredPoor drug metabolizer, lower dose requirement.Details
Cytochrome P450 2D6CYP2D6*11Not Available883G>CEffect InferredPoor drug metabolizer, lower dose requirement.Details
Cytochrome P450 2D6CYP2D6*12Not Available124G>AEffect InferredPoor drug metabolizer, lower dose requirement.Details
Cytochrome P450 2D6CYP2D6*13Not AvailableCYP2D7/2D6 hybrid gene structureEffect InferredPoor drug metabolizer, lower dose requirement.Details
Cytochrome P450 2D6CYP2D6*14ANot Available1758G>AEffect InferredPoor drug metabolizer, lower dose requirement.Details
Cytochrome P450 2D6CYP2D6*15Not Available137insT, 137_138insTEffect InferredPoor drug metabolizer, lower dose requirement.Details
Cytochrome P450 2D6CYP2D6*19Not Available2539_2542delAACTEffect InferredPoor drug metabolizer, lower dose requirement.Details
Cytochrome P450 2D6CYP2D6*20Not Available1973_1974insGEffect InferredPoor drug metabolizer, lower dose requirement.Details
Cytochrome P450 2D6CYP2D6*21Not Available2573insCEffect InferredPoor drug metabolizer, lower dose requirement.Details
Cytochrome P450 2D6CYP2D6*31Not Available-1770G>A / -1584C>G  … show all Effect InferredPoor drug metabolizer, lower dose requirement.Details
Cytochrome P450 2D6CYP2D6*36Not Available100C>T / -1426C>T  … show all Effect InferredPoor drug metabolizer, lower dose requirement.Details
Cytochrome P450 2D6CYP2D6*38Not Available2587_2590delGACTEffect InferredPoor drug metabolizer, lower dose requirement.Details
Cytochrome P450 2D6CYP2D6*40Not Available1863_1864ins(TTT CGC CCC)2Effect InferredPoor drug metabolizer, lower dose requirement.Details
Cytochrome P450 2D6CYP2D6*42Not Available3259_3260insGTEffect InferredPoor drug metabolizer, lower dose requirement.Details
Cytochrome P450 2D6CYP2D6*44Not Available2950G>CEffect InferredPoor drug metabolizer, lower dose requirement.Details
Cytochrome P450 2D6CYP2D6*47Not Available100C>T / -1426C>T  … show all Effect InferredPoor drug metabolizer, lower dose requirement.Details
Cytochrome P450 2D6CYP2D6*51Not Available-1584C>G / -1235A>G  … show all Effect InferredPoor drug metabolizer, lower dose requirement.Details
Cytochrome P450 2D6CYP2D6*56Not Available3201C>TEffect InferredPoor drug metabolizer, lower dose requirement.Details
Cytochrome P450 2D6CYP2D6*57Not Available100C>T / 310G>T  … show all Effect InferredPoor drug metabolizer, lower dose requirement.Details
Cytochrome P450 2D6CYP2D6*62Not Available4044C>TEffect InferredPoor drug metabolizer, lower dose requirement.Details
Cytochrome P450 2D6CYP2D6*68ANot Available-1426C>T / -1235A>G  … show all Effect InferredPoor drug metabolizer, lower dose requirement.Details
Cytochrome P450 2D6CYP2D6*68BNot AvailableSimilar but not identical switch region compared to CYP2D6*68A. Found in tandem arrangement with CYP2D6*4.Effect InferredPoor drug metabolizer, lower dose requirement.Details
Cytochrome P450 2D6CYP2D6*69Not Available2988G>A / -1426C>T  … show all Effect InferredPoor drug metabolizer, lower dose requirement.Details
Cytochrome P450 2D6CYP2D6*92Not Available1995delCEffect InferredPoor drug metabolizer, lower dose requirement.Details
Cytochrome P450 2D6CYP2D6*100Not Available-1426C>T / -1235A>G  … show all Effect InferredPoor drug metabolizer, lower dose requirement.Details
Cytochrome P450 2D6CYP2D6*101Not Available-1426C>T / -1235A>G  … show all Effect InferredPoor drug metabolizer, lower dose requirement.Details

Interactions

Drug Interactions
DrugInteractionDrug group
(1S,6R)-3-{[3-(TRIFLUOROMETHYL)-5,6-DIHYDRO[1,2,4]TRIAZOLO[4,3-A]PYRAZIN-7(8H)-YL]CARBONYL}-6-(2,4,5-TRIFLUOROPHENYL)CYCLOHEX-3-EN-1-AMINEThe therapeutic efficacy of (1S,6R)-3-{[3-(TRIFLUOROMETHYL)-5,6-DIHYDRO[1,2,4]TRIAZOLO[4,3-A]PYRAZIN-7(8H)-YL]CARBONYL}-6-(2,4,5-TRIFLUOROPHENYL)CYCLOHEX-3-EN-1-AMINE can be decreased when used in combination with Iloperidone.Experimental
2,4-thiazolidinedioneThe therapeutic efficacy of 2,4-thiazolidinedione can be decreased when used in combination with Iloperidone.Investigational
2,5-Dimethoxy-4-ethylamphetamineIloperidone may decrease the stimulatory activities of 2,5-Dimethoxy-4-ethylamphetamine.Experimental, Illicit
2,5-Dimethoxy-4-ethylthioamphetamineIloperidone may decrease the stimulatory activities of 2,5-Dimethoxy-4-ethylthioamphetamine.Experimental
3,4-MethylenedioxyamphetamineIloperidone may decrease the stimulatory activities of 3,4-Methylenedioxyamphetamine.Experimental, Illicit
4-Bromo-2,5-dimethoxyamphetamineIloperidone may decrease the stimulatory activities of 4-Bromo-2,5-dimethoxyamphetamine.Experimental, Illicit
4-MethoxyamphetamineIloperidone may decrease the vasoconstricting activities of 4-Methoxyamphetamine.Experimental, Illicit
7-NitroindazoleThe risk or severity of adverse effects can be increased when Iloperidone is combined with 7-Nitroindazole.Experimental
AbirateroneThe serum concentration of Iloperidone can be increased when it is combined with Abiraterone.Approved
AcarboseThe therapeutic efficacy of Acarbose can be decreased when used in combination with Iloperidone.Approved, Investigational
AcebutololAcebutolol may increase the orthostatic hypotensive activities of Iloperidone.Approved, Investigational
AcepromazineAcepromazine may increase the antihypertensive activities of Iloperidone.Approved, Vet Approved
AceprometazineThe risk or severity of adverse effects can be increased when Iloperidone is combined with Aceprometazine.Approved
AcetohexamideThe therapeutic efficacy of Acetohexamide can be decreased when used in combination with Iloperidone.Approved, Investigational, Withdrawn
Acetyl sulfisoxazoleThe metabolism of Iloperidone can be decreased when combined with Acetyl sulfisoxazole.Approved, Vet Approved
AdipiplonThe risk or severity of adverse effects can be increased when Iloperidone is combined with Adipiplon.Investigational
AdrafinilIloperidone may decrease the vasoconstricting activities of Adrafinil.Withdrawn
AgmatineIloperidone may decrease the vasoconstricting activities of Agmatine.Experimental, Investigational
AgomelatineThe risk or severity of adverse effects can be increased when Iloperidone is combined with Agomelatine.Approved, Investigational
AICA ribonucleotideThe therapeutic efficacy of AICA ribonucleotide can be decreased when used in combination with Iloperidone.Experimental, Investigational
AlaproclateThe risk or severity of adverse effects can be increased when Iloperidone is combined with Alaproclate.Experimental
AlfaxaloneThe risk or severity of adverse effects can be increased when Iloperidone is combined with Alfaxalone.Vet Approved
AlfentanilThe risk or severity of adverse effects can be increased when Alfentanil is combined with Iloperidone.Approved, Illicit
AlfuzosinAlfuzosin may increase the antihypertensive activities of Iloperidone.Approved, Investigational
AllicinThe therapeutic efficacy of Allicin can be decreased when used in combination with Iloperidone.Investigational
AllopregnanoloneThe risk or severity of adverse effects can be increased when Iloperidone is combined with Allopregnanolone.Investigational
AlmotriptanThe risk or severity of adverse effects can be increased when Almotriptan is combined with Iloperidone.Approved, Investigational
AlogliptinThe therapeutic efficacy of Alogliptin can be decreased when used in combination with Iloperidone.Approved
AlphacetylmethadolThe risk or severity of adverse effects can be increased when Iloperidone is combined with Alphacetylmethadol.Experimental, Illicit
AlphaprodineThe risk or severity of adverse effects can be increased when Iloperidone is combined with Alphaprodine.Illicit
AlprazolamThe risk or severity of adverse effects can be increased when Alprazolam is combined with Iloperidone.Approved, Illicit, Investigational
AlprenololAlprenolol may increase the orthostatic hypotensive activities of Iloperidone.Approved, Withdrawn
AmantadineThe therapeutic efficacy of Amantadine can be decreased when used in combination with Iloperidone.Approved
AmibegronIloperidone may decrease the vasoconstricting activities of Amibegron.Investigational
AmiodaroneThe serum concentration of the active metabolites of Iloperidone can be increased when Iloperidone is used in combination with Amiodarone.Approved, Investigational
AmisulprideIloperidone may increase the antipsychotic activities of Amisulpride.Approved, Investigational
AmitrazIloperidone may decrease the vasoconstricting activities of Amitraz.Vet Approved
AmitriptylineAmitriptyline may increase the antihypertensive activities of Iloperidone.Approved
AmlodipineThe risk or severity of hypotension can be increased when Iloperidone is combined with Amlodipine.Approved
AmobarbitalThe risk or severity of adverse effects can be increased when Amobarbital is combined with Iloperidone.Approved, Illicit
AmoxapineAmoxapine may increase the antihypertensive activities of Iloperidone.Approved
AmperozideThe risk or severity of adverse effects can be increased when Iloperidone is combined with Amperozide.Experimental
AmphetamineIloperidone may decrease the stimulatory activities of Amphetamine.Approved, Illicit, Investigational
AmrinoneThe risk or severity of hypotension can be increased when Iloperidone is combined with Amrinone.Approved
AnagrelideThe risk or severity of QTc prolongation can be increased when Anagrelide is combined with Iloperidone.Approved
AnisodamineIloperidone may decrease the vasoconstricting activities of Anisodamine.Investigational
ApalutamideThe serum concentration of Iloperidone can be decreased when it is combined with Apalutamide.Approved, Investigational
ApomorphineThe therapeutic efficacy of Apomorphine can be decreased when used in combination with Iloperidone.Approved, Investigational
ApraclonidineIloperidone may decrease the vasoconstricting activities of Apraclonidine.Approved
AprepitantThe serum concentration of Iloperidone can be increased when it is combined with Aprepitant.Approved, Investigational
AranidipineThe risk or severity of hypotension can be increased when Iloperidone is combined with Aranidipine.Approved, Investigational
ArbutamineIloperidone may decrease the vasoconstricting activities of Arbutamine.Approved
ArformoterolArformoterol may increase the QTc-prolonging activities of Iloperidone.Approved, Investigational
AripiprazoleAripiprazole may increase the antihypertensive activities of Iloperidone.Approved, Investigational
ArotinololArotinolol may increase the orthostatic hypotensive activities of Iloperidone.Investigational
Arsenic trioxideThe risk or severity of QTc prolongation can be increased when Arsenic trioxide is combined with Iloperidone.Approved, Investigational
ArtemetherThe risk or severity of QTc prolongation can be increased when Iloperidone is combined with Artemether.Approved
ArticaineThe risk or severity of adverse effects can be increased when Iloperidone is combined with Articaine.Approved
AsenapineThe risk or severity of QTc prolongation can be increased when Iloperidone is combined with Asenapine.Approved
AsunaprevirThe serum concentration of Asunaprevir can be increased when it is combined with Iloperidone.Approved, Investigational, Withdrawn
AtazanavirThe serum concentration of the active metabolites of Iloperidone can be increased when Iloperidone is used in combination with Atazanavir.Approved, Investigational
AtenololAtenolol may increase the orthostatic hypotensive activities of Iloperidone.Approved
AtomoxetineAtomoxetine may increase the QTc-prolonging activities of Iloperidone.Approved
AtorvastatinThe risk or severity of adverse effects can be increased when Iloperidone is combined with Atorvastatin.Approved
AvanafilAvanafil may increase the hypotensive activities of Iloperidone.Approved
AzaperoneThe risk or severity of adverse effects can be increased when Iloperidone is combined with Azaperone.Investigational, Vet Approved
AzelastineIloperidone may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved
AzelnidipineThe risk or severity of hypotension can be increased when Iloperidone is combined with Azelnidipine.Approved, Investigational
AzimilideThe risk or severity of hypotension can be increased when Iloperidone is combined with Azimilide.Investigational
AzithromycinAzithromycin may increase the QTc-prolonging activities of Iloperidone.Approved
BaclofenThe risk or severity of adverse effects can be increased when Baclofen is combined with Iloperidone.Approved
BalaglitazoneThe therapeutic efficacy of Balaglitazone can be decreased when used in combination with Iloperidone.Investigational
BambuterolIloperidone may decrease the vasoconstricting activities of Bambuterol.Approved, Investigational
BarbitalThe risk or severity of adverse effects can be increased when Iloperidone is combined with Barbital.Illicit
BarnidipineThe risk or severity of hypotension can be increased when Iloperidone is combined with Barnidipine.Approved
BedaquilineBedaquiline may increase the QTc-prolonging activities of Iloperidone.Approved
BefunololBefunolol may increase the orthostatic hypotensive activities of Iloperidone.Experimental
Bempedoic acidThe therapeutic efficacy of Bempedoic acid can be decreased when used in combination with Iloperidone.Investigational
BencyclaneThe risk or severity of hypotension can be increased when Iloperidone is combined with Bencyclane.Experimental
BenidipineThe risk or severity of hypotension can be increased when Iloperidone is combined with Benidipine.Approved, Investigational
BenperidolThe risk or severity of adverse effects can be increased when Iloperidone is combined with Benperidol.Approved, Investigational
BenzocaineThe risk or severity of adverse effects can be increased when Iloperidone is combined with Benzocaine.Approved, Investigational
BenzphetamineIloperidone may decrease the stimulatory activities of Benzphetamine.Approved, Illicit
Benzyl alcoholThe risk or severity of adverse effects can be increased when Iloperidone is combined with Benzyl alcohol.Approved
Benzylpenicilloyl PolylysineIloperidone may decrease effectiveness of Benzylpenicilloyl Polylysine as a diagnostic agent.Approved
BepridilThe risk or severity of hypotension can be increased when Iloperidone is combined with Bepridil.Approved, Withdrawn
BetahistineThe therapeutic efficacy of Betahistine can be decreased when used in combination with Iloperidone.Approved, Investigational
BetaxololBetaxolol may increase the orthostatic hypotensive activities of Iloperidone.Approved, Investigational
BevantololBevantolol may increase the antihypertensive activities of Iloperidone.Approved
BioallethrinThe risk or severity of hypotension can be increased when Iloperidone is combined with Bioallethrin.Approved, Experimental
BisoprololBisoprolol may increase the orthostatic hypotensive activities of Iloperidone.Approved
BitolterolIloperidone may decrease the vasoconstricting activities of Bitolterol.Withdrawn
BoceprevirThe serum concentration of the active metabolites of Iloperidone can be increased when Iloperidone is used in combination with Boceprevir.Approved, Withdrawn
BopindololBopindolol may increase the orthostatic hypotensive activities of Iloperidone.Approved
BortezomibBortezomib may increase the QTc-prolonging activities of Iloperidone.Approved, Investigational
BosentanThe serum concentration of Iloperidone can be decreased when it is combined with Bosentan.Approved, Investigational
BosutinibThe serum concentration of Bosutinib can be increased when it is combined with Iloperidone.Approved
BrexpiprazoleIloperidone may increase the antihypertensive activities of Brexpiprazole.Approved, Investigational
BrimonidineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Iloperidone.Approved
BromazepamThe risk or severity of adverse effects can be increased when Bromazepam is combined with Iloperidone.Approved, Illicit, Investigational
BromisovalThe risk or severity of adverse effects can be increased when Iloperidone is combined with Bromisoval.Experimental
BromocriptineThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Iloperidone.Approved, Investigational
BromperidolThe risk or severity of adverse effects can be increased when Iloperidone is combined with Bromperidol.Approved, Investigational
BrompheniramineThe risk or severity of adverse effects can be increased when Brompheniramine is combined with Iloperidone.Approved
BrotizolamThe risk or severity of adverse effects can be increased when Iloperidone is combined with Brotizolam.Approved, Investigational, Withdrawn
BucindololBucindolol may increase the antihypertensive activities of Iloperidone.Investigational
BuforminThe therapeutic efficacy of Buformin can be decreased when used in combination with Iloperidone.Investigational, Withdrawn
BufuralolBufuralol may increase the orthostatic hypotensive activities of Iloperidone.Experimental, Investigational
BunazosinBunazosin may increase the antihypertensive activities of Iloperidone.Investigational
BupivacaineThe risk or severity of adverse effects can be increased when Iloperidone is combined with Bupivacaine.Approved, Investigational
BupranololBupranolol may increase the orthostatic hypotensive activities of Iloperidone.Approved
BuprenorphineIloperidone may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.Approved, Illicit, Investigational, Vet Approved
BupropionThe serum concentration of the active metabolites of Iloperidone can be increased when Iloperidone is used in combination with Bupropion.Approved
BuserelinBuserelin may increase the QTc-prolonging activities of Iloperidone.Approved, Investigational
BuspironeThe risk or severity of adverse effects can be increased when Buspirone is combined with Iloperidone.Approved, Investigational
ButabarbitalThe risk or severity of adverse effects can be increased when Butabarbital is combined with Iloperidone.Approved, Illicit
ButacaineThe risk or severity of adverse effects can be increased when Iloperidone is combined with Butacaine.Vet Approved
ButalbitalThe risk or severity of adverse effects can be increased when Butalbital is combined with Iloperidone.Approved, Illicit
ButambenThe risk or severity of adverse effects can be increased when Iloperidone is combined with Butamben.Approved, Withdrawn
ButethalThe risk or severity of adverse effects can be increased when Iloperidone is combined with Butethal.Approved, Illicit
ButorphanolThe risk or severity of adverse effects can be increased when Butorphanol is combined with Iloperidone.Approved, Illicit, Vet Approved
CabergolineThe risk or severity of adverse effects can be increased when Cabergoline is combined with Iloperidone.Approved
CaffeineThe metabolism of Iloperidone can be decreased when combined with Caffeine.Approved
CanagliflozinThe therapeutic efficacy of Canagliflozin can be decreased when used in combination with Iloperidone.Approved
CanertinibThe risk or severity of adverse effects can be increased when Iloperidone is combined with Canertinib.Investigational
CarbamazepineThe metabolism of Iloperidone can be increased when combined with Carbamazepine.Approved, Investigational
CarbinoxamineThe risk or severity of adverse effects can be increased when Carbinoxamine is combined with Iloperidone.Approved
CarboxyamidotriazoleThe risk or severity of hypotension can be increased when Iloperidone is combined with Carboxyamidotriazole.Investigational
CarbutamideThe therapeutic efficacy of Carbutamide can be decreased when used in combination with Iloperidone.Experimental
CarfentanilThe risk or severity of adverse effects can be increased when Iloperidone is combined with Carfentanil.Illicit, Investigational, Vet Approved
CarisoprodolThe risk or severity of adverse effects can be increased when Carisoprodol is combined with Iloperidone.Approved
CaroverineThe risk or severity of hypotension can be increased when Iloperidone is combined with Caroverine.Experimental
CarteololCarteolol may increase the orthostatic hypotensive activities of Iloperidone.Approved
CarvedilolCarvedilol may increase the antihypertensive activities of Iloperidone.Approved, Investigational
CastanospermineThe therapeutic efficacy of Castanospermine can be decreased when used in combination with Iloperidone.Experimental
CelecoxibThe metabolism of Iloperidone can be decreased when combined with Celecoxib.Approved, Investigational
CeliprololCeliprolol may increase the orthostatic hypotensive activities of Iloperidone.Approved, Investigational
CeritinibThe serum concentration of the active metabolites of Iloperidone can be increased when Iloperidone is used in combination with Ceritinib.Approved
CerivastatinThe serum concentration of Cerivastatin can be increased when it is combined with Iloperidone.Approved, Withdrawn
CetirizineThe risk or severity of adverse effects can be increased when Cetirizine is combined with Iloperidone.Approved
Chloral hydrateThe risk or severity of adverse effects can be increased when Iloperidone is combined with Chloral hydrate.Approved, Illicit, Investigational, Vet Approved
ChlordiazepoxideThe risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Iloperidone.Approved, Illicit, Investigational
ChlormezanoneThe risk or severity of adverse effects can be increased when Iloperidone is combined with Chlormezanone.Approved, Investigational, Withdrawn
ChloroprocaineThe risk or severity of adverse effects can be increased when Iloperidone is combined with Chloroprocaine.Approved
ChloroquineChloroquine may increase the QTc-prolonging activities of Iloperidone.Approved, Investigational, Vet Approved
ChlorphenamineThe risk or severity of adverse effects can be increased when Chlorphenamine is combined with Iloperidone.Approved
ChlorphentermineIloperidone may decrease the stimulatory activities of Chlorphentermine.Illicit, Withdrawn
ChlorpromazineChlorpromazine may increase the QTc-prolonging activities of Iloperidone.Approved, Investigational, Vet Approved
ChlorpropamideThe therapeutic efficacy of Chlorpropamide can be decreased when used in combination with Iloperidone.Approved, Investigational
ChlorprothixeneThe risk or severity of adverse effects can be increased when Iloperidone is combined with Chlorprothixene.Approved, Investigational, Withdrawn
ChlorzoxazoneThe risk or severity of adverse effects can be increased when Chlorzoxazone is combined with Iloperidone.Approved
CholecalciferolThe metabolism of Iloperidone can be decreased when combined with Cholecalciferol.Approved, Nutraceutical
CiglitazoneThe therapeutic efficacy of Ciglitazone can be decreased when used in combination with Iloperidone.Experimental
CilnidipineThe risk or severity of hypotension can be increased when Iloperidone is combined with Cilnidipine.Approved, Investigational
CimetidineThe metabolism of Iloperidone can be decreased when combined with Cimetidine.Approved, Investigational
CinacalcetThe serum concentration of the active metabolites of Iloperidone can be increased when Iloperidone is used in combination with Cinacalcet.Approved
CinchocaineThe risk or severity of adverse effects can be increased when Iloperidone is combined with Cinchocaine.Approved, Vet Approved
CinnarizineThe risk or severity of hypotension can be increased when Iloperidone is combined with Cinnarizine.Approved, Investigational
CiprofloxacinCiprofloxacin may increase the QTc-prolonging activities of Iloperidone.Approved, Investigational
CirazolineIloperidone may decrease the vasoconstricting activities of Cirazoline.Experimental
CisaprideThe risk or severity of QTc prolongation can be increased when Cisapride is combined with Iloperidone.Approved, Investigational, Withdrawn
CitalopramThe risk or severity of QTc prolongation can be increased when Citalopram is combined with Iloperidone.Approved
ClarithromycinThe serum concentration of the active metabolites of Iloperidone can be increased when Iloperidone is used in combination with Clarithromycin.Approved
ClemastineThe metabolism of Iloperidone can be decreased when combined with Clemastine.Approved, Investigational
ClenbuterolIloperidone may decrease the vasoconstricting activities of Clenbuterol.Approved, Investigational, Vet Approved
ClevidipineThe risk or severity of hypotension can be increased when Iloperidone is combined with Clevidipine.Approved, Investigational
ClidiniumThe risk or severity of adverse effects can be increased when Clidinium is combined with Iloperidone.Approved
ClobazamThe metabolism of Iloperidone can be decreased when combined with Clobazam.Approved, Illicit
clomethiazoleThe risk or severity of adverse effects can be increased when Iloperidone is combined with clomethiazole.Investigational
ClomipramineClomipramine may increase the QTc-prolonging activities of Iloperidone.Approved, Investigational, Vet Approved
ClonazepamThe risk or severity of adverse effects can be increased when Clonazepam is combined with Iloperidone.Approved, Illicit
ClonidineThe risk or severity of adverse effects can be increased when Clonidine is combined with Iloperidone.Approved
ClopenthixolThe risk or severity of adverse effects can be increased when Iloperidone is combined with Clopenthixol.Experimental
CloranololCloranolol may increase the orthostatic hypotensive activities of Iloperidone.Experimental
ClorazepateThe risk or severity of adverse effects can be increased when Clorazepate is combined with Iloperidone.Approved, Illicit
ClothiapineThe risk or severity of adverse effects can be increased when Iloperidone is combined with Clothiapine.Experimental
ClotrimazoleThe metabolism of Iloperidone can be decreased when combined with Clotrimazole.Approved, Vet Approved
ClozapineClozapine may increase the QTc-prolonging activities of Iloperidone.Approved
CobicistatThe serum concentration of the active metabolites of Iloperidone can be increased when Iloperidone is used in combination with Cobicistat.Approved
CocaineThe serum concentration of the active metabolites of Iloperidone can be increased when Iloperidone is used in combination with Cocaine.Approved, Illicit
CodeineThe risk or severity of adverse effects can be increased when Codeine is combined with Iloperidone.Approved, Illicit
ConivaptanThe serum concentration of Conivaptan can be increased when it is combined with Iloperidone.Approved, Investigational
CrizotinibCrizotinib may increase the QTc-prolonging activities of Iloperidone.Approved
CurcuminThe serum concentration of the active metabolites of Iloperidone can be increased when Iloperidone is used in combination with Curcumin.Approved, Investigational
CyclandelateThe risk or severity of hypotension can be increased when Iloperidone is combined with Cyclandelate.Approved
CyclizineThe risk or severity of adverse effects can be increased when Cyclizine is combined with Iloperidone.Approved
CyclobenzaprineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Iloperidone.Approved
CyclopropaneThe risk or severity of adverse effects can be increased when Iloperidone is combined with Cyclopropane.Experimental
CyclosporineThe metabolism of Iloperidone can be decreased when combined with Cyclosporine.Approved, Investigational, Vet Approved
CyproheptadineThe risk or severity of adverse effects can be increased when Cyproheptadine is combined with Iloperidone.Approved
Cyproterone acetateThe serum concentration of Iloperidone can be decreased when it is combined with Cyproterone acetate.Approved, Investigational
DabrafenibThe serum concentration of Iloperidone can be decreased when it is combined with Dabrafenib.Approved, Investigational
DantroleneThe risk or severity of adverse effects can be increased when Dantrolene is combined with Iloperidone.Approved, Investigational
DapiprazoleDapiprazole may increase the antihypertensive activities of Iloperidone.Approved
DapoxetineDapoxetine may increase the orthostatic hypotensive activities of Iloperidone.Investigational
DarifenacinThe metabolism of Iloperidone can be decreased when combined with Darifenacin.Approved, Investigational
DarodipineThe risk or severity of hypotension can be increased when Iloperidone is combined with Darodipine.Experimental
DarunavirThe serum concentration of the active metabolites of Iloperidone can be increased when Iloperidone is used in combination with Darunavir.Approved
DasatinibThe serum concentration of Iloperidone can be increased when it is combined with Dasatinib.Approved, Investigational
DeferasiroxThe serum concentration of Iloperidone can be decreased when it is combined with Deferasirox.Approved, Investigational
DegarelixDegarelix may increase the QTc-prolonging activities of Iloperidone.Approved
DelavirdineThe serum concentration of the active metabolites of Iloperidone can be increased when Iloperidone is used in combination with Delavirdine.Approved
DeoxyspergualinThe therapeutic efficacy of Deoxyspergualin can be decreased when used in combination with Iloperidone.Investigational
DeramciclaneThe risk or severity of adverse effects can be increased when Iloperidone is combined with Deramciclane.Investigational
DesfluraneDesflurane may increase the QTc-prolonging activities of Iloperidone.Approved
DesipramineDesipramine may increase the QTc-prolonging activities of Iloperidone.Approved, Investigational
DesloratadineThe risk or severity of adverse effects can be increased when Desloratadine is combined with Iloperidone.Approved, Investigational
DesvenlafaxineThe risk or severity of adverse effects can be increased when Desvenlafaxine is combined with Iloperidone.Approved, Investigational
DetomidineThe risk or severity of adverse effects can be increased when Iloperidone is combined with Detomidine.Vet Approved
DeutetrabenazineThe risk or severity of adverse effects can be increased when Iloperidone is combined with Deutetrabenazine.Approved, Investigational
DexbrompheniramineThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Iloperidone.Approved
DexmedetomidineThe risk or severity of adverse effects can be increased when Iloperidone is combined with Dexmedetomidine.Approved, Vet Approved
DextroamphetamineIloperidone may increase the antihypertensive activities of Dextroamphetamine.Approved, Illicit
DextromethorphanThe risk or severity of adverse effects can be increased when Dextromethorphan is combined with Iloperidone.Approved
DextromoramideThe risk or severity of adverse effects can be increased when Iloperidone is combined with Dextromoramide.Experimental, Illicit
DextropropoxypheneThe risk or severity of adverse effects can be increased when Iloperidone is combined with Dextropropoxyphene.Approved, Illicit, Investigational, Withdrawn
DezocineThe risk or severity of adverse effects can be increased when Iloperidone is combined with Dezocine.Approved, Investigational
DiazepamThe risk or severity of adverse effects can be increased when Diazepam is combined with Iloperidone.Approved, Illicit, Investigational, Vet Approved
Diethyl etherThe risk or severity of adverse effects can be increased when Iloperidone is combined with Diethyl ether.Experimental
DiethylpropionIloperidone may decrease the stimulatory activities of Diethylpropion.Approved, Illicit
DifenoxinThe risk or severity of adverse effects can be increased when Difenoxin is combined with Iloperidone.Approved, Illicit
DihydrocodeineThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Iloperidone.Approved, Illicit
DihydroergocornineThe risk or severity of adverse effects can be increased when Dihydroergocornine is combined with Iloperidone.Approved
DihydroergocristineThe risk or severity of adverse effects can be increased when Dihydroergocristine is combined with Iloperidone.Approved, Experimental
DihydroergocryptineThe risk or severity of adverse effects can be increased when Dihydroergocryptine is combined with Iloperidone.Experimental
DihydroergotamineThe risk or severity of adverse effects can be increased when Dihydroergotamine is combined with Iloperidone.Approved, Investigational
DihydroetorphineThe risk or severity of adverse effects can be increased when Iloperidone is combined with Dihydroetorphine.Experimental, Illicit
DihydromorphineThe risk or severity of adverse effects can be increased when Iloperidone is combined with Dihydromorphine.Experimental, Illicit
DiltiazemThe metabolism of Iloperidone can be decreased when combined with Diltiazem.Approved, Investigational
DimenhydrinateThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Iloperidone.Approved
DiphenhydramineDiphenhydramine may increase the QTc-prolonging activities of Iloperidone.Approved, Investigational
DiphenoxylateThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Iloperidone.Approved, Illicit
DipivefrinIloperidone may decrease the vasoconstricting activities of Dipivefrin.Approved
DipyridamoleDipyridamole may increase the hypotensive activities of Iloperidone.Approved
DisopyramideThe risk or severity of QTc prolongation can be increased when Disopyramide is combined with Iloperidone.Approved
DixyrazineThe risk or severity of adverse effects can be increased when Iloperidone is combined with Dixyrazine.Experimental
DL-MethylephedrineIloperidone may decrease the vasoconstricting activities of DL-Methylephedrine.Approved
DobutamineIloperidone may decrease the vasoconstricting activities of Dobutamine.Approved
DofetilideThe risk or severity of QTc prolongation can be increased when Dofetilide is combined with Iloperidone.Approved, Investigational
DolasetronDolasetron may increase the QTc-prolonging activities of Iloperidone.Approved, Investigational
DomperidoneThe risk or severity of QTc prolongation can be increased when Domperidone is combined with Iloperidone.Approved, Investigational, Vet Approved
DopexamineIloperidone may decrease the vasoconstricting activities of Dopexamine.Approved, Investigational
DoramectinThe risk or severity of adverse effects can be increased when Iloperidone is combined with Doramectin.Vet Approved
DosulepinThe serum concentration of the active metabolites of Iloperidone can be increased when Iloperidone is used in combination with Dosulepin.Approved
DotarizineThe risk or severity of hypotension can be increased when Iloperidone is combined with Dotarizine.Investigational
DoxazosinDoxazosin may increase the antihypertensive activities of Iloperidone.Approved
DoxepinDoxepin may increase the antihypertensive activities of Iloperidone.Approved, Investigational
DoxofyllineIloperidone may decrease the vasoconstricting activities of Doxofylline.Approved, Investigational
DoxycyclineThe metabolism of Iloperidone can be decreased when combined with Doxycycline.Approved, Investigational, Vet Approved
DoxylamineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Iloperidone.Approved, Vet Approved
DPDPEThe risk or severity of adverse effects can be increased when Iloperidone is combined with DPDPE.Experimental
DronabinolDronabinol may increase the central nervous system depressant (CNS depressant) activities of Iloperidone.Approved, Illicit
DronedaroneThe risk or severity of QTc prolongation can be increased when Dronedarone is combined with Iloperidone.Approved
DroperidolDroperidol may increase the central nervous system depressant (CNS depressant) activities of Iloperidone.Approved, Vet Approved
DrotebanolThe risk or severity of adverse effects can be increased when Iloperidone is combined with Drotebanol.Experimental, Illicit
DroxidopaIloperidone may decrease the vasoconstricting activities of Droxidopa.Approved, Investigational
DulaglutideThe therapeutic efficacy of Dulaglutide can be decreased when used in combination with Iloperidone.Approved, Investigational
DuloxetineThe metabolism of Iloperidone can be decreased when combined with Duloxetine.Approved
DyclonineThe risk or severity of adverse effects can be increased when Iloperidone is combined with Dyclonine.Approved
EcgonineThe risk or severity of adverse effects can be increased when Iloperidone is combined with Ecgonine.Experimental, Illicit
EcopipamThe risk or severity of adverse effects can be increased when Iloperidone is combined with Ecopipam.Investigational
EfavirenzThe risk or severity of adverse effects can be increased when Efavirenz is combined with Iloperidone.Approved, Investigational
EfonidipineThe risk or severity of hypotension can be increased when Iloperidone is combined with Efonidipine.Approved, Investigational
EletriptanThe risk or severity of adverse effects can be increased when Eletriptan is combined with Iloperidone.Approved, Investigational
EliglustatThe risk or severity of QTc prolongation can be increased when Iloperidone is combined with Eliglustat.Approved
EltanoloneThe risk or severity of adverse effects can be increased when Iloperidone is combined with Eltanolone.Investigational
EmpagliflozinThe therapeutic efficacy of Empagliflozin can be decreased when used in combination with Iloperidone.Approved
EnfluraneThe risk or severity of adverse effects can be increased when Iloperidone is combined with Enflurane.Approved, Investigational, Vet Approved
EnglitazoneThe therapeutic efficacy of Englitazone can be decreased when used in combination with Iloperidone.Experimental
EntacaponeThe risk or severity of adverse effects can be increased when Entacapone is combined with Iloperidone.Approved, Investigational
EnzalutamideThe serum concentration of Iloperidone can be decreased when it is combined with Enzalutamide.Approved
EpanololEpanolol may increase the orthostatic hypotensive activities of Iloperidone.Experimental
EperisoneThe risk or severity of hypotension can be increased when Iloperidone is combined with Eperisone.Approved, Investigational
EphedraIloperidone may decrease the vasoconstricting activities of Ephedra.Approved, Nutraceutical, Withdrawn
EphedrineIloperidone may decrease the vasoconstricting activities of Ephedrine.Approved
EpinastineIloperidone may decrease the vasoconstricting activities of Epinastine.Approved, Investigational
EpinephrineIloperidone may increase the antihypertensive activities of Epinephrine.Approved, Vet Approved
Ergoloid mesylateThe risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Iloperidone.Approved
ErgonovineThe risk or severity of adverse effects can be increased when Ergonovine is combined with Iloperidone.Approved
ErgotamineThe risk or severity of adverse effects can be increased when Ergotamine is combined with Iloperidone.Approved
EribulinEribulin may increase the QTc-prolonging activities of Iloperidone.Approved, Investigational
ErythromycinErythromycin may increase the QTc-prolonging activities of Iloperidone.Approved, Investigational, Vet Approved
EsatenololEsatenolol may increase the orthostatic hypotensive activities of Iloperidone.Experimental
EscitalopramThe risk or severity of QTc prolongation can be increased when Escitalopram is combined with Iloperidone.Approved, Investigational
EsmololEsmolol may increase the orthostatic hypotensive activities of Iloperidone.Approved
EstazolamThe risk or severity of adverse effects can be increased when Estazolam is combined with Iloperidone.Approved, Illicit
EszopicloneThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Iloperidone.Approved, Investigational
EtafedrineIloperidone may decrease the vasoconstricting activities of Etafedrine.Approved
EthanolIloperidone may increase the central nervous system depressant (CNS depressant) activities of Ethanol.Approved
EthchlorvynolThe risk or severity of adverse effects can be increased when Iloperidone is combined with Ethchlorvynol.Approved, Illicit, Withdrawn
EthosuximideThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Iloperidone.Approved
EthotoinThe risk or severity of adverse effects can be increased when Ethotoin is combined with Iloperidone.Approved
Ethyl carbamateThe risk or severity of adverse effects can be increased when Iloperidone is combined with Ethyl carbamate.Withdrawn
Ethyl chlorideThe risk or severity of adverse effects can be increased when Iloperidone is combined with Ethyl chloride.Approved, Experimental, Investigational
Ethyl loflazepateThe risk or severity of adverse effects can be increased when Iloperidone is combined with Ethyl loflazepate.Approved, Illicit
EthylmorphineThe risk or severity of adverse effects can be increased when Iloperidone is combined with Ethylmorphine.Approved, Illicit
EtidocaineThe risk or severity of adverse effects can be increased when Iloperidone is combined with Etidocaine.Approved
EtifoxineThe risk or severity of adverse effects can be increased when Iloperidone is combined with Etifoxine.Investigational, Withdrawn
EtilefrineIloperidone may decrease the vasoconstricting activities of Etilefrine.Withdrawn
EtizolamThe risk or severity of adverse effects can be increased when Iloperidone is combined with Etizolam.Approved
EtomidateThe risk or severity of adverse effects can be increased when Iloperidone is combined with Etomidate.Approved
EtoperidoneThe risk or severity of adverse effects can be increased when Iloperidone is combined with Etoperidone.Withdrawn
EtorphineThe risk or severity of adverse effects can be increased when Iloperidone is combined with Etorphine.Illicit, Vet Approved
ExenatideThe therapeutic efficacy of Exenatide can be decreased when used in combination with Iloperidone.Approved, Investigational
EzogabineEzogabine may increase the QTc-prolonging activities of Iloperidone.Approved, Investigational
FamotidineFamotidine may increase the QTc-prolonging activities of Iloperidone.Approved
FelbamateFelbamate may increase the QTc-prolonging activities of Iloperidone.Approved
FelodipineThe risk or severity of hypotension can be increased when Iloperidone is combined with Felodipine.Approved, Investigational
FencamfamineThe risk or severity of adverse effects can be increased when Iloperidone is combined with Fencamfamine.Approved, Illicit, Withdrawn
FendilineThe risk or severity of hypotension can be increased when Iloperidone is combined with Fendiline.Withdrawn
FenoterolIloperidone may decrease the vasoconstricting activities of Fenoterol.Approved, Investigational
FentanylThe risk or severity of adverse effects can be increased when Fentanyl is combined with Iloperidone.Approved, Illicit, Investigational, Vet Approved
FexofenadineThe risk or severity of adverse effects can be increased when Fexofenadine is combined with Iloperidone.Approved, Investigational
FingolimodFingolimod may increase the QTc-prolonging activities of Iloperidone.Approved, Investigational
Fish oilThe risk or severity of hypotension can be increased when Iloperidone is combined with Fish oil.Approved, Nutraceutical
FlecainideFlecainide may increase the QTc-prolonging activities of Iloperidone.Approved, Withdrawn
FlibanserinThe risk or severity of adverse effects can be increased when Flibanserin is combined with Iloperidone.Approved, Investigational
FluanisoneThe risk or severity of adverse effects can be increased when Iloperidone is combined with Fluanisone.Experimental
FluconazoleFluconazole may increase the QTc-prolonging activities of Iloperidone.Approved, Investigational
FludiazepamThe risk or severity of adverse effects can be increased when Iloperidone is combined with Fludiazepam.Approved, Illicit
FlunarizineThe risk or severity of adverse effects can be increased when Flunarizine is combined with Iloperidone.Approved
FlunitrazepamThe risk or severity of adverse effects can be increased when Iloperidone is combined with Flunitrazepam.Approved, Illicit
FluoxetineThe serum concentration of the active metabolites of Iloperidone can be increased when Iloperidone is used in combination with Fluoxetine.Approved, Vet Approved
FlupentixolThe risk or severity of QTc prolongation can be increased when Flupentixol is combined with Iloperidone.Approved, Investigational, Withdrawn
FluphenazineThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Iloperidone.Approved
FlurazepamThe risk or severity of adverse effects can be increased when Flurazepam is combined with Iloperidone.Approved, Illicit, Investigational
FluspirileneThe risk or severity of adverse effects can be increased when Iloperidone is combined with Fluspirilene.Approved, Investigational
Fluticasone propionateThe risk or severity of adverse effects can be increased when Fluticasone propionate is combined with Iloperidone.Approved
FluvastatinThe serum concentration of Fluvastatin can be increased when it is combined with Iloperidone.Approved
FluvoxamineThe metabolism of Iloperidone can be decreased when combined with Fluvoxamine.Approved, Investigational
FormoterolFormoterol may increase the QTc-prolonging activities of Iloperidone.Approved, Investigational
FosamprenavirThe metabolism of Iloperidone can be decreased when combined with Fosamprenavir.Approved
FosaprepitantThe serum concentration of Iloperidone can be increased when it is combined with Fosaprepitant.Approved
FoscarnetFoscarnet may increase the QTc-prolonging activities of Iloperidone.Approved
FosphenytoinThe metabolism of Iloperidone can be increased when combined with Fosphenytoin.Approved, Investigational
FospropofolThe risk or severity of adverse effects can be increased when Iloperidone is combined with Fospropofol.Approved, Illicit, Investigational
FostamatinibFostamatinib may increase the hypotensive activities of Iloperidone.Approved, Investigational
FrovatriptanThe risk or severity of adverse effects can be increased when Frovatriptan is combined with Iloperidone.Approved, Investigational
Fusidic AcidThe serum concentration of Iloperidone can be increased when it is combined with Fusidic Acid.Approved, Investigational
GabapentinThe risk or severity of adverse effects can be increased when Gabapentin is combined with Iloperidone.Approved, Investigational
Gabapentin EnacarbilThe risk or severity of adverse effects can be increased when Iloperidone is combined with Gabapentin Enacarbil.Approved, Investigational
Gadobenic acidGadobenic acid may increase the QTc-prolonging activities of Iloperidone.Approved, Investigational
GalantamineGalantamine may increase the QTc-prolonging activities of Iloperidone.Approved
GallopamilThe risk or severity of hypotension can be increased when Iloperidone is combined with Gallopamil.Investigational
Gamma Hydroxybutyric AcidThe risk or severity of adverse effects can be increased when Gamma Hydroxybutyric Acid is combined with Iloperidone.Approved, Illicit, Investigational
GemifloxacinGemifloxacin may increase the QTc-prolonging activities of Iloperidone.Approved, Investigational
GepefrineIloperidone may decrease the stimulatory activities of Gepefrine.Experimental
GepironeThe risk or severity of adverse effects can be increased when Iloperidone is combined with Gepirone.Investigational
GlibornurideThe therapeutic efficacy of Glibornuride can be decreased when used in combination with Iloperidone.Investigational, Withdrawn
GliclazideThe therapeutic efficacy of Gliclazide can be decreased when used in combination with Iloperidone.Approved
GlimepirideThe therapeutic efficacy of Glimepiride can be decreased when used in combination with Iloperidone.Approved
GlipizideThe therapeutic efficacy of Glipizide can be decreased when used in combination with Iloperidone.Approved, Investigational
GliquidoneThe therapeutic efficacy of Gliquidone can be decreased when used in combination with Iloperidone.Approved, Investigational
GlutethimideThe risk or severity of adverse effects can be increased when Iloperidone is combined with Glutethimide.Approved, Illicit
GlyburideThe therapeutic efficacy of Glyburide can be decreased when used in combination with Iloperidone.Approved
GoserelinGoserelin may increase the QTc-prolonging activities of Iloperidone.Approved
GranisetronGranisetron may increase the QTc-prolonging activities of Iloperidone.Approved, Investigational
GuanabenzIloperidone may decrease the vasoconstricting activities of Guanabenz.Approved, Investigational
GuanfacineThe risk or severity of adverse effects can be increased when Guanfacine is combined with Iloperidone.Approved, Investigational
GusperimusThe therapeutic efficacy of Gusperimus can be decreased when used in combination with Iloperidone.Investigational
HalazepamThe risk or severity of adverse effects can be increased when Iloperidone is combined with Halazepam.Approved, Illicit, Withdrawn
HaloperidolHaloperidol may increase the QTc-prolonging activities of Iloperidone.Approved
HalothaneThe risk or severity of adverse effects can be increased when Iloperidone is combined with Halothane.Approved, Vet Approved
HeroinThe risk or severity of adverse effects can be increased when Iloperidone is combined with Heroin.Approved, Illicit, Investigational
HexobarbitalThe risk or severity of adverse effects can be increased when Iloperidone is combined with Hexobarbital.Approved
HexoprenalineIloperidone may decrease the vasoconstricting activities of Hexoprenaline.Approved, Withdrawn
HigenamineIloperidone may decrease the vasoconstricting activities of Higenamine.Investigational
HistrelinHistrelin may increase the QTc-prolonging activities of Iloperidone.Approved
HyaluronidaseThe therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Iloperidone.Approved, Investigational
HydrocodoneIloperidone may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Illicit
HydromorphoneThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Iloperidone.Approved, Illicit
HydroxyamphetamineIloperidone may decrease the stimulatory activities of Hydroxyamphetamine.Approved
HydroxyzineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Iloperidone.Approved
IbandronateIbandronate may increase the QTc-prolonging activities of Iloperidone.Approved, Investigational
IbrutinibThe serum concentration of Ibrutinib can be increased when it is combined with Iloperidone.Approved
IbutilideThe risk or severity of QTc prolongation can be increased when Ibutilide is combined with Iloperidone.Approved
IdelalisibThe serum concentration of the active metabolites of Iloperidone can be increased when Iloperidone is used in combination with Idelalisib.Approved
ImatinibThe metabolism of Iloperidone can be decreased when combined with Imatinib.Approved
ImipramineImipramine may increase the antihypertensive activities of Iloperidone.Approved
IndacaterolIndacaterol may increase the QTc-prolonging activities of Iloperidone.Approved
IndalpineThe risk or severity of adverse effects can be increased when Iloperidone is combined with Indalpine.Investigational, Withdrawn
IndapamideIndapamide may increase the QTc-prolonging activities of Iloperidone.Approved
IndenololIndenolol may increase the orthostatic hypotensive activities of Iloperidone.Withdrawn
IndinavirThe serum concentration of the active metabolites of Iloperidone can be increased when Iloperidone is used in combination with Indinavir.Approved
IndiplonThe risk or severity of adverse effects can be increased when Iloperidone is combined with Indiplon.Investigational
IndoraminIndoramin may increase the antihypertensive activities of Iloperidone.Withdrawn
Insulin AspartThe therapeutic efficacy of Insulin Aspart can be decreased when used in combination with Iloperidone.Approved
Insulin DetemirThe therapeutic efficacy of Insulin Detemir can be decreased when used in combination with Iloperidone.Approved
Insulin GlargineThe therapeutic efficacy of Insulin Glargine can be decreased when used in combination with Iloperidone.Approved
Insulin GlulisineThe therapeutic efficacy of Insulin Glulisine can be decreased when used in combination with Iloperidone.Approved
Insulin HumanThe therapeutic efficacy of Insulin Human can be decreased when used in combination with Iloperidone.Approved, Investigational
Insulin LisproThe therapeutic efficacy of Insulin Lispro can be decreased when used in combination with Iloperidone.Approved
Insulin PorkThe therapeutic efficacy of Insulin Pork can be decreased when used in combination with Iloperidone.Approved
Iofetamine I-123Iloperidone may decrease the stimulatory activities of Iofetamine I-123.Approved
IsavuconazoleThe serum concentration of Iloperidone can be increased when it is combined with Isavuconazole.Approved, Investigational
IsavuconazoniumThe metabolism of Iloperidone can be decreased when combined with Isavuconazonium.Approved, Investigational
IsocarboxazidThe risk or severity of adverse effects can be increased when Isocarboxazid is combined with Iloperidone.Approved
IsoetarineIloperidone may decrease the vasoconstricting activities of Isoetarine.Approved
IsofluraneIsoflurane may increase the QTc-prolonging activities of Iloperidone.Approved, Vet Approved
IsomethepteneIloperidone may decrease the vasoconstricting activities of Isometheptene.Approved
IsoniazidThe metabolism of Iloperidone can be decreased when combined with Isoniazid.Approved, Investigational
IsoprenalineIloperidone may decrease the vasoconstricting activities of Isoprenaline.Approved, Investigational
IsoxsuprineIloperidone may decrease the vasoconstricting activities of Isoxsuprine.Approved, Withdrawn
IsradipineIsradipine may increase the QTc-prolonging activities of Iloperidone.Approved, Investigational
ItraconazoleThe serum concentration of the active metabolites of Iloperidone can be increased when Iloperidone is used in combination with Itraconazole.Approved, Investigational
IvabradineIloperidone may increase the QTc-prolonging activities of Ivabradine.Approved
IvacaftorThe serum concentration of Iloperidone can be increased when it is combined with Ivacaftor.Approved
KetamineThe risk or severity of adverse effects can be increased when Ketamine is combined with Iloperidone.Approved, Vet Approved
KetazolamThe risk or severity of adverse effects can be increased when Iloperidone is combined with Ketazolam.Approved
KetobemidoneThe risk or severity of adverse effects can be increased when Iloperidone is combined with Ketobemidone.Approved, Investigational
KetoconazoleThe serum concentration of the active metabolites of Iloperidone can be increased when Iloperidone is used in combination with Ketoconazole.Approved, Investigational
LabetalolLabetalol may increase the antihypertensive activities of Iloperidone.Approved
LacidipineThe risk or severity of hypotension can be increased when Iloperidone is combined with Lacidipine.Approved, Investigational
LamotrigineThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Iloperidone.Approved, Investigational
LandiololLandiolol may increase the orthostatic hypotensive activities of Iloperidone.Investigational
LapatinibLapatinib may increase the QTc-prolonging activities of Iloperidone.Approved, Investigational
LenvatinibLenvatinib may increase the QTc-prolonging activities of Iloperidone.Approved, Investigational
LercanidipineThe risk or severity of hypotension can be increased when Iloperidone is combined with Lercanidipine.Approved, Investigational
LeuprolideLeuprolide may increase the QTc-prolonging activities of Iloperidone.Approved, Investigational
LevetiracetamThe risk or severity of adverse effects can be increased when Levetiracetam is combined with Iloperidone.Approved, Investigational
LevobetaxololLevobetaxolol may increase the orthostatic hypotensive activities of Iloperidone.Approved, Investigational
LevobupivacaineThe risk or severity of adverse effects can be increased when Iloperidone is combined with Levobupivacaine.Approved, Investigational
LevocabastineThe risk or severity of adverse effects can be increased when Iloperidone is combined with Levocabastine.Approved, Investigational
LevocetirizineThe risk or severity of adverse effects can be increased when Iloperidone is combined with Levocetirizine.Approved
LevodopaThe therapeutic efficacy of Levodopa can be decreased when used in combination with Iloperidone.Approved
LevofloxacinLevofloxacin may increase the QTc-prolonging activities of Iloperidone.Approved, Investigational
Levomethadyl AcetateThe risk or severity of adverse effects can be increased when Iloperidone is combined with Levomethadyl Acetate.Approved, Investigational
LevomilnacipranThe risk or severity of adverse effects can be increased when Levomilnacipran is combined with Iloperidone.Approved, Investigational
LevorphanolThe risk or severity of adverse effects can be increased when Levorphanol is combined with Iloperidone.Approved
LevosalbutamolIloperidone may decrease the vasoconstricting activities of Levosalbutamol.Approved, Investigational
LidocaineThe metabolism of Iloperidone can be decreased when combined with Lidocaine.Approved, Vet Approved
LidoflazineThe risk or severity of hypotension can be increased when Iloperidone is combined with Lidoflazine.Experimental
LinagliptinThe therapeutic efficacy of Linagliptin can be decreased when used in combination with Iloperidone.Approved
LinezolidThe risk or severity of adverse effects can be increased when Linezolid is combined with Iloperidone.Approved, Investigational
LiraglutideThe therapeutic efficacy of Liraglutide can be decreased when used in combination with Iloperidone.Approved
LisdexamfetamineIloperidone may increase the antihypertensive activities of Lisdexamfetamine.Approved, Investigational
LisurideThe risk or severity of adverse effects can be increased when Lisuride is combined with Iloperidone.Approved, Investigational
Lithium cationLithium may increase the neurotoxic activities of Iloperidone.Experimental
LobeglitazoneThe metabolism of Iloperidone can be decreased when combined with Lobeglitazone.Approved, Investigational
LofentanilThe risk or severity of adverse effects can be increased when Iloperidone is combined with Lofentanil.Illicit
LofexidineThe therapeutic efficacy of Iloperidone can be increased when used in combination with Lofexidine.Approved, Investigational
LoperamideThe risk or severity of hypotension can be increased when Iloperidone is combined with Loperamide.Approved
LopinavirThe serum concentration of the active metabolites of Iloperidone can be increased when Iloperidone is used in combination with Lopinavir.Approved
LoprazolamThe risk or severity of adverse effects can be increased when Iloperidone is combined with Loprazolam.Experimental
LoratadineThe risk or severity of adverse effects can be increased when Loratadine is combined with Iloperidone.Approved, Investigational
LorazepamThe risk or severity of adverse effects can be increased when Lorazepam is combined with Iloperidone.Approved
LorcaserinThe metabolism of Iloperidone can be decreased when combined with Lorcaserin.Approved
LormetazepamThe risk or severity of adverse effects can be increased when Iloperidone is combined with Lormetazepam.Approved
LorpiprazoleThe serum concentration of Iloperidone can be increased when it is combined with Lorpiprazole.Approved
LovastatinThe serum concentration of Lovastatin can be increased when it is combined with Iloperidone.Approved, Investigational
LoxapineThe risk or severity of adverse effects can be increased when Loxapine is combined with Iloperidone.Approved
LuliconazoleThe serum concentration of Iloperidone can be increased when it is combined with Luliconazole.Approved
LumacaftorThe metabolism of Iloperidone can be increased when combined with Lumacaftor.Approved
LumefantrineThe risk or severity of QTc prolongation can be increased when Iloperidone is combined with Lumefantrine.Approved
LurasidoneThe risk or severity of adverse effects can be increased when Lurasidone is combined with Iloperidone.Approved, Investigational
Lysergic Acid DiethylamideThe risk or severity of adverse effects can be increased when Lysergic Acid Diethylamide is combined with Iloperidone.Illicit, Investigational, Withdrawn
Magnesium sulfateThe therapeutic efficacy of Iloperidone can be increased when used in combination with Magnesium sulfate.Approved, Investigational, Vet Approved
ManidipineThe metabolism of Iloperidone can be decreased when combined with Manidipine.Approved, Investigational
MaprotilineMaprotiline may increase the QTc-prolonging activities of Iloperidone.Approved, Investigational
MebicarThe risk or severity of adverse effects can be increased when Iloperidone is combined with Mebicar.Experimental
MeclizineThe risk or severity of adverse effects can be increased when Meclizine is combined with Iloperidone.Approved
MedazepamThe risk or severity of adverse effects can be increased when Iloperidone is combined with Medazepam.Experimental
MedetomidineThe risk or severity of adverse effects can be increased when Iloperidone is combined with Medetomidine.Vet Approved
MefloquineMefloquine may increase the QTc-prolonging activities of Iloperidone.Approved, Investigational
MelatoninThe risk or severity of adverse effects can be increased when Iloperidone is combined with Melatonin.Approved, Nutraceutical, Vet Approved
MelperoneThe risk or severity of adverse effects can be increased when Iloperidone is combined with Melperone.Approved, Investigational
MentholThe risk or severity of hypotension can be increased when Iloperidone is combined with Menthol.Approved
MephedroneIloperidone may decrease the stimulatory activities of Mephedrone.Investigational
MephentermineIloperidone may decrease the stimulatory activities of Mephentermine.Approved
MepindololMepindolol may increase the orthostatic hypotensive activities of Iloperidone.Experimental
MepivacaineThe risk or severity of adverse effects can be increased when Iloperidone is combined with Mepivacaine.Approved, Vet Approved
MeprobamateThe risk or severity of adverse effects can be increased when Meprobamate is combined with Iloperidone.Approved, Illicit
MeptazinolThe risk or severity of adverse effects can be increased when Iloperidone is combined with Meptazinol.Experimental
MequitazineIloperidone may increase the arrhythmogenic activities of Mequitazine.Approved
MesoridazineThe risk or severity of adverse effects can be increased when Iloperidone is combined with Mesoridazine.Approved, Investigational
MetaraminolIloperidone may decrease the vasoconstricting activities of Metaraminol.Approved, Investigational
MetaxaloneThe risk or severity of adverse effects can be increased when Metaxalone is combined with Iloperidone.Approved
MetergolineThe risk or severity of adverse effects can be increased when Metergoline is combined with Iloperidone.Experimental
MetforminThe therapeutic efficacy of Metformin can be decreased when used in combination with Iloperidone.Approved
MethadoneMethadone may increase the QTc-prolonging activities of Iloperidone.Approved
Methadyl AcetateThe risk or severity of adverse effects can be increased when Iloperidone is combined with Methadyl Acetate.Approved, Illicit
MethamphetamineIloperidone may decrease the stimulatory activities of Methamphetamine.Approved, Illicit
MethapyrileneThe risk or severity of adverse effects can be increased when Iloperidone is combined with Methapyrilene.Withdrawn
MethaqualoneThe risk or severity of adverse effects can be increased when Iloperidone is combined with Methaqualone.Illicit, Withdrawn
MethocarbamolThe risk or severity of adverse effects can be increased when Methocarbamol is combined with Iloperidone.Approved, Vet Approved
MethohexitalThe risk or severity of adverse effects can be increased when Methohexital is combined with Iloperidone.Approved
MethotrimeprazineThe serum concentration of the active metabolites of Iloperidone can be increased when Iloperidone is used in combination with Methotrimeprazine.Approved, Investigational
MethoxamineIloperidone may decrease the vasoconstricting activities of Methoxamine.Approved, Investigational
MethoxyfluraneThe risk or severity of adverse effects can be increased when Iloperidone is combined with Methoxyflurane.Approved, Investigational, Vet Approved
MethoxyphenamineIloperidone may decrease the stimulatory activities of Methoxyphenamine.Experimental
MethsuximideThe risk or severity of adverse effects can be increased when Iloperidone is combined with Methsuximide.Approved
MethyldopaIloperidone may decrease the vasoconstricting activities of Methyldopa.Approved
MethylecgonineThe risk or severity of adverse effects can be increased when Iloperidone is combined with Methylecgonine.Experimental
MethylergometrineThe risk or severity of adverse effects can be increased when Methylergometrine is combined with Iloperidone.Approved
MethylphenidateThe risk or severity of adverse effects can be increased when Iloperidone is combined with Methylphenidate.Approved, Investigational
MethylphenobarbitalThe risk or severity of adverse effects can be increased when Iloperidone is combined with Methylphenobarbital.Approved
MethysergideThe risk or severity of adverse effects can be increased when Methysergide is combined with Iloperidone.Approved
MetoclopramideThe risk or severity of adverse effects can be increased when Metoclopramide is combined with Iloperidone.Approved, Investigational
MetoclopramideMetoclopramide may increase the QTc-prolonging activities of Iloperidone.Approved, Investigational
MetoprololMetoprolol may increase the orthostatic hypotensive activities of Iloperidone.Approved, Investigational
MetronidazoleMetronidazole may increase the QTc-prolonging activities of Iloperidone.Approved
MetyrosineThe risk or severity of adverse effects can be increased when Metyrosine is combined with Iloperidone.Approved
MevastatinThe serum concentration of Mevastatin can be increased when it is combined with Iloperidone.Experimental
MexiletineThe metabolism of Iloperidone can be decreased when combined with Mexiletine.Approved, Investigational
MibefradilThe risk or severity of hypotension can be increased when Iloperidone is combined with Mibefradil.Investigational, Withdrawn
MidazolamThe risk or severity of adverse effects can be increased when Midazolam is combined with Iloperidone.Approved, Illicit
MidodrineIloperidone may decrease the vasoconstricting activities of Midodrine.Approved
MidomafetamineIloperidone may decrease the stimulatory activities of Midomafetamine.Experimental, Illicit, Investigational
MidostaurinThe serum concentration of the active metabolites of Iloperidone can be increased when Iloperidone is used in combination with Midostaurin.Approved, Investigational
MifepristoneIloperidone may increase the QTc-prolonging activities of Mifepristone.Approved, Investigational
MiglitolThe therapeutic efficacy of Miglitol can be decreased when used in combination with Iloperidone.Approved
MiglustatThe therapeutic efficacy of Miglustat can be decreased when used in combination with Iloperidone.Approved
MilnacipranThe risk or severity of adverse effects can be increased when Milnacipran is combined with Iloperidone.Approved, Investigational
MinocyclineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Iloperidone.Approved, Investigational
MirabegronMirabegron may increase the QTc-prolonging activities of Iloperidone.Approved
MirodenafilMirodenafil may increase the hypotensive activities of Iloperidone.Investigational
MirtazapineIloperidone may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.Approved
MitiglinideThe therapeutic efficacy of Mitiglinide can be decreased when used in combination with Iloperidone.Approved, Investigational
MitotaneThe serum concentration of Iloperidone can be decreased when it is combined with Mitotane.Approved
MMDAIloperidone may decrease the stimulatory activities of MMDA.Experimental, Illicit
MoclobemideThe risk or severity of adverse effects can be increased when Moclobemide is combined with Iloperidone.Approved, Investigational
MoexiprilMoexipril may increase the QTc-prolonging activities of Iloperidone.Approved
MolindoneThe risk or severity of adverse effects can be increased when Iloperidone is combined with Molindone.Approved
MorphineThe risk or severity of adverse effects can be increased when Morphine is combined with Iloperidone.Approved, Investigational
MoxifloxacinMoxifloxacin may increase the QTc-prolonging activities of Iloperidone.Approved, Investigational
MoxonidineIloperidone may decrease the vasoconstricting activities of Moxonidine.Approved, Investigational
NabiloneNabilone may increase the central nervous system depressant (CNS depressant) activities of Iloperidone.Approved, Investigational
NadololNadolol may increase the orthostatic hypotensive activities of Iloperidone.Approved
NaftopidilThe risk or severity of hypotension can be increased when Iloperidone is combined with Naftopidil.Investigational
NalbuphineThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Iloperidone.Approved
NaphazolineIloperidone may decrease the vasoconstricting activities of Naphazoline.Approved
NaratriptanThe risk or severity of adverse effects can be increased when Naratriptan is combined with Iloperidone.Approved, Investigational
NateglinideThe therapeutic efficacy of Nateglinide can be decreased when used in combination with Iloperidone.Approved, Investigational
NebivololNebivolol may increase the orthostatic hypotensive activities of Iloperidone.Approved, Investigational
NefazodoneThe serum concentration of the active metabolites of Iloperidone can be increased when Iloperidone is used in combination with Nefazodone.Approved, Withdrawn
NelfinavirThe serum concentration of the active metabolites of Iloperidone can be increased when Iloperidone is used in combination with Nelfinavir.Approved
NetupitantThe serum concentration of Iloperidone can be increased when it is combined with Netupitant.Approved, Investigational
NevirapineThe metabolism of Iloperidone can be increased when combined with Nevirapine.Approved
NicardipineNicardipine may increase the antihypertensive activities of Iloperidone.Approved, Investigational
NicergolineThe risk or severity of adverse effects can be increased when Nicergoline is combined with Iloperidone.Approved, Investigational
NicotineThe metabolism of Iloperidone can be decreased when combined with Nicotine.Approved
NifedipineThe risk or severity of hypotension can be increased when Iloperidone is combined with Nifedipine.Approved
NiguldipineIloperidone may increase the antihypertensive activities of Niguldipine.Experimental
NilotinibThe risk or severity of QTc prolongation can be increased when Nilotinib is combined with Iloperidone.Approved, Investigational
NiludipineThe risk or severity of hypotension can be increased when Iloperidone is combined with Niludipine.Experimental
NilvadipineThe risk or severity of hypotension can be increased when Iloperidone is combined with Nilvadipine.Approved, Investigational
NimesulideThe risk or severity of hypotension can be increased when Iloperidone is combined with Nimesulide.Approved, Investigational, Withdrawn
NimodipineThe risk or severity of hypotension can be increased when Iloperidone is combined with Nimodipine.Approved, Investigational
NisoldipineThe risk or severity of hypotension can be increased when Iloperidone is combined with Nisoldipine.Approved
NitrazepamThe risk or severity of adverse effects can be increased when Nitrazepam is combined with Iloperidone.Approved
NitrendipineThe risk or severity of hypotension can be increased when Iloperidone is combined with Nitrendipine.Approved, Investigational
Nitrous oxideThe risk or severity of adverse effects can be increased when Nitrous oxide is combined with Iloperidone.Approved, Vet Approved
NordazepamThe risk or severity of adverse effects can be increased when Iloperidone is combined with Nordazepam.Approved
NorepinephrineIloperidone may decrease the vasoconstricting activities of Norepinephrine.Approved
NorfenefrineIloperidone may decrease the vasoconstricting activities of Norfenefrine.Experimental
NorfloxacinNorfloxacin may increase the QTc-prolonging activities of Iloperidone.Approved
NorfluraneThe risk or severity of adverse effects can be increased when Iloperidone is combined with Norflurane.Approved, Investigational
NormethadoneThe risk or severity of adverse effects can be increased when Iloperidone is combined with Normethadone.Approved, Illicit
NortriptylineNortriptyline may increase the antihypertensive activities of Iloperidone.Approved
NylidrinIloperidone may decrease the vasoconstricting activities of Nylidrin.Approved
OctopamineIloperidone may decrease the vasoconstricting activities of Octopamine.Experimental
OctreotideOctreotide may increase the QTc-prolonging activities of Iloperidone.Approved, Investigational
OfloxacinOfloxacin may increase the QTc-prolonging activities of Iloperidone.Approved
OlanzapineOlanzapine may increase the antihypertensive activities of Iloperidone.Approved, Investigational
OlaparibThe metabolism of Iloperidone can be decreased when combined with Olaparib.Approved
OlodaterolOlodaterol may increase the QTc-prolonging activities of Iloperidone.Approved
OlopatadineThe risk or severity of adverse effects can be increased when Olopatadine is combined with Iloperidone.Approved
OndansetronOndansetron may increase the QTc-prolonging activities of Iloperidone.Approved
OpiumThe risk or severity of adverse effects can be increased when Iloperidone is combined with Opium.Approved, Illicit
OrciprenalineIloperidone may decrease the vasoconstricting activities of Orciprenaline.Approved
OrphenadrineIloperidone may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.Approved
OsanetantThe risk or severity of adverse effects can be increased when Iloperidone is combined with Osanetant.Investigational
OsimertinibThe serum concentration of Iloperidone can be increased when it is combined with Osimertinib.Approved
OtiloniumThe risk or severity of hypotension can be increased when Iloperidone is combined with Otilonium.Experimental, Investigational
OxazepamThe risk or severity of adverse effects can be increased when Oxazepam is combined with Iloperidone.Approved
OxprenololOxprenolol may increase the orthostatic hypotensive activities of Iloperidone.Approved
OxybuprocaineThe risk or severity of adverse effects can be increased when Iloperidone is combined with Oxybuprocaine.Approved, Investigational
OxycodoneThe risk or severity of adverse effects can be increased when Oxycodone is combined with Iloperidone.Approved, Illicit, Investigational
OxyfedrineIloperidone may decrease the vasoconstricting activities of Oxyfedrine.Experimental
OxymetazolineIloperidone may decrease the vasoconstricting activities of Oxymetazoline.Approved, Investigational
OxymorphoneThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Iloperidone.Approved, Investigational, Vet Approved
OxytocinOxytocin may increase the QTc-prolonging activities of Iloperidone.Approved, Vet Approved
PalbociclibThe serum concentration of Iloperidone can be increased when it is combined with Palbociclib.Approved, Investigational
PaliperidoneThe risk or severity of QTc prolongation can be increased when Paliperidone is combined with Iloperidone.Approved
PanobinostatThe serum concentration of Iloperidone can be increased when it is combined with Panobinostat.Approved, Investigational
ParaldehydeIloperidone may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.Approved, Investigational
ParoxetineThe serum concentration of the active metabolites of Iloperidone can be increased when Iloperidone is used in combination with Paroxetine.Approved, Investigational
PasireotidePasireotide may increase the QTc-prolonging activities of Iloperidone.Approved
PazopanibPazopanib may increase the QTc-prolonging activities of Iloperidone.Approved
Peginterferon alfa-2bThe serum concentration of Iloperidone can be decreased when it is combined with Peginterferon alfa-2b.Approved
PenbutololPenbutolol may increase the orthostatic hypotensive activities of Iloperidone.Approved, Investigational
PenfluridolThe risk or severity of adverse effects can be increased when Iloperidone is combined with Penfluridol.Experimental
PentamidinePentamidine may increase the QTc-prolonging activities of Iloperidone.Approved, Investigational
PentazocineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Iloperidone.Approved, Vet Approved
PentobarbitalThe metabolism of Iloperidone can be increased when combined with Pentobarbital.Approved, Investigational, Vet Approved
PentoxifyllinePentoxifylline may increase the hypotensive activities of Iloperidone.Approved, Investigational
PerampanelPerampanel may increase the central nervous system depressant (CNS depressant) activities of Iloperidone.Approved
PerazineThe risk or severity of adverse effects can be increased when Iloperidone is combined with Perazine.Approved, Investigational
PerflutrenPerflutren may increase the QTc-prolonging activities of Iloperidone.Approved
PergolideThe risk or severity of adverse effects can be increased when Pergolide is combined with Iloperidone.Approved, Investigational, Vet Approved, Withdrawn
PerospironeThe risk or severity of adverse effects can be increased when Iloperidone is combined with Perospirone.Approved
PerphenazineThe risk or severity of adverse effects can be increased when Perphenazine is combined with Iloperidone.Approved
PethidineThe risk or severity of adverse effects can be increased when Pethidine is combined with Iloperidone.Approved
PhenazocineThe risk or severity of adverse effects can be increased when Iloperidone is combined with Phenazocine.Experimental
PhendimetrazineIloperidone may decrease the vasoconstricting activities of Phendimetrazine.Approved, Illicit
PhenelzineThe risk or severity of adverse effects can be increased when Phenelzine is combined with Iloperidone.Approved
PhenforminThe therapeutic efficacy of Phenformin can be decreased when used in combination with Iloperidone.Approved, Investigational, Withdrawn
PhenibutThe risk or severity of adverse effects can be increased when Iloperidone is combined with Phenibut.Experimental
PhenobarbitalThe metabolism of Iloperidone can be increased when combined with Phenobarbital.Approved, Investigational
PhenoperidineThe risk or severity of adverse effects can be increased when Iloperidone is combined with Phenoperidine.Experimental
PhenoxybenzaminePhenoxybenzamine may increase the antihypertensive activities of Iloperidone.Approved
PhenoxyethanolThe risk or severity of adverse effects can be increased when Iloperidone is combined with Phenoxyethanol.Approved
PhentermineIloperidone may decrease the stimulatory activities of Phentermine.Approved, Illicit
PhentolaminePhentolamine may increase the antihypertensive activities of Iloperidone.Approved
PhenylephrineIloperidone may decrease the vasoconstricting activities of Phenylephrine.Approved
PhenylpropanolamineIloperidone may decrease the vasoconstricting activities of Phenylpropanolamine.Approved, Vet Approved, Withdrawn
PhenytoinThe metabolism of Iloperidone can be increased when combined with Phenytoin.Approved, Vet Approved
PimozideThe risk or severity of QTc prolongation can be increased when Pimozide is combined with Iloperidone.Approved
PinaveriumThe risk or severity of hypotension can be increased when Iloperidone is combined with Pinaverium.Approved
PindololPindolol may increase the orthostatic hypotensive activities of Iloperidone.Approved, Investigational
PioglitazoneThe therapeutic efficacy of Pioglitazone can be decreased when used in combination with Iloperidone.Approved, Investigational
PipamperoneThe risk or severity of adverse effects can be increased when Iloperidone is combined with Pipamperone.Approved, Investigational
PipotiazineThe risk or severity of adverse effects can be increased when Pipotiazine is combined with Iloperidone.Approved, Investigational
PirbuterolIloperidone may decrease the vasoconstricting activities of Pirbuterol.Approved
PiribedilThe therapeutic efficacy of Piribedil can be decreased when used in combination with Iloperidone.Investigational
PiritramideThe risk or severity of adverse effects can be increased when Iloperidone is combined with Piritramide.Approved, Investigational
PitavastatinThe serum concentration of Pitavastatin can be increased when it is combined with Iloperidone.Approved
PitolisantThe serum concentration of Iloperidone can be decreased when it is combined with Pitolisant.Approved, Investigational
PizotifenIloperidone may increase the antihypertensive activities of Pizotifen.Approved
Platelet Activating FactorPlatelet Activating Factor may increase the orthostatic hypotensive activities of Iloperidone.Experimental
PomalidomideThe risk or severity of adverse effects can be increased when Iloperidone is combined with Pomalidomide.Approved
PosaconazoleThe serum concentration of the active metabolites of Iloperidone can be increased when Iloperidone is used in combination with Posaconazole.Approved, Investigational, Vet Approved
PractololPractolol may increase the orthostatic hypotensive activities of Iloperidone.Approved
PramipexoleIloperidone may increase the sedative activities of Pramipexole.Approved, Investigational
PramlintideThe therapeutic efficacy of Pramlintide can be decreased when used in combination with Iloperidone.Approved, Investigational
PramocaineThe risk or severity of adverse effects can be increased when Iloperidone is combined with Pramocaine.Approved
PravastatinThe serum concentration of Pravastatin can be increased when it is combined with Iloperidone.Approved
PrazepamThe risk or severity of adverse effects can be increased when Iloperidone is combined with Prazepam.Approved, Illicit
PrazosinPrazosin may increase the antihypertensive activities of Iloperidone.Approved
PregabalinThe therapeutic efficacy of Iloperidone can be increased when used in combination with Pregabalin.Approved, Illicit, Investigational
PrenalterolIloperidone may decrease the vasoconstricting activities of Prenalterol.Experimental
PrenylamineThe risk or severity of hypotension can be increased when Iloperidone is combined with Prenylamine.Withdrawn
PrilocaineThe risk or severity of adverse effects can be increased when Iloperidone is combined with Prilocaine.Approved
PrimaquinePrimaquine may increase the QTc-prolonging activities of Iloperidone.Approved
PrimidoneThe metabolism of Iloperidone can be increased when combined with Primidone.Approved, Vet Approved
ProcainamideThe risk or severity of QTc prolongation can be increased when Procainamide is combined with Iloperidone.Approved
ProcaineThe risk or severity of adverse effects can be increased when Iloperidone is combined with Procaine.Approved, Investigational, Vet Approved
ProcarbazineThe risk or severity of adverse effects can be increased when Procarbazine is combined with Iloperidone.Approved, Investigational
ProcaterolIloperidone may decrease the vasoconstricting activities of Procaterol.Approved, Investigational
ProchlorperazineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Iloperidone.Approved, Vet Approved
PromazinePromazine may increase the QTc-prolonging activities of Iloperidone.Approved, Vet Approved
PromethazinePromethazine may increase the QTc-prolonging activities of Iloperidone.Approved, Investigational
PropafenonePropafenone may increase the QTc-prolonging activities of Iloperidone.Approved
PropanididThe risk or severity of adverse effects can be increased when Iloperidone is combined with Propanidid.Experimental
ProparacaineThe risk or severity of adverse effects can be increased when Iloperidone is combined with Proparacaine.Approved, Vet Approved
PropericiazineIloperidone may increase the antihypertensive activities of Propericiazine.Approved, Investigational
PropiomazinePropiomazine may increase the antihypertensive activities of Iloperidone.Approved
PropiverineIloperidone may increase the antihypertensive activities of Propiverine.Approved, Investigational
PropofolPropofol may increase the QTc-prolonging activities of Iloperidone.Approved, Investigational, Vet Approved
PropoxycaineThe risk or severity of adverse effects can be increased when Iloperidone is combined with Propoxycaine.Approved
PropranololPropranolol may increase the orthostatic hypotensive activities of Iloperidone.Approved, Investigational
ProtokylolIloperidone may decrease the vasoconstricting activities of Protokylol.Approved, Vet Approved
ProtriptylineProtriptyline may increase the QTc-prolonging activities of Iloperidone.Approved
ProxibarbalThe risk or severity of adverse effects can be increased when Iloperidone is combined with Proxibarbal.Experimental
PSD502The risk or severity of adverse effects can be increased when Iloperidone is combined with PSD502.Investigational
PseudoephedrineIloperidone may decrease the stimulatory activities of Pseudoephedrine.Approved
QuazepamThe risk or severity of adverse effects can be increased when Quazepam is combined with Iloperidone.Approved, Illicit
QuetiapineThe risk or severity of QTc prolongation can be increased when Quetiapine is combined with Iloperidone.Approved
QuinagolideThe therapeutic efficacy of Quinagolide can be decreased when used in combination with Iloperidone.Approved, Investigational
QuinidineThe serum concentration of the active metabolites of Iloperidone can be increased when Iloperidone is used in combination with Quinidine.Approved, Investigational
QuinineThe risk or severity of QTc prolongation can be increased when Quinine is combined with Iloperidone.Approved
QuinisocaineThe risk or severity of adverse effects can be increased when Iloperidone is combined with Quinisocaine.Experimental
RacepinephrineIloperidone may increase the antihypertensive activities of Racepinephrine.Approved
RacloprideThe risk or severity of adverse effects can be increased when Iloperidone is combined with Raclopride.Investigational
RactopamineIloperidone may decrease the vasoconstricting activities of Ractopamine.Vet Approved
RamelteonThe risk or severity of adverse effects can be increased when Ramelteon is combined with Iloperidone.Approved, Investigational
RanolazineRanolazine may increase the QTc-prolonging activities of Iloperidone.Approved, Investigational
RasagilineThe risk or severity of adverse effects can be increased when Rasagiline is combined with Iloperidone.Approved
RemifentanilThe risk or severity of adverse effects can be increased when Remifentanil is combined with Iloperidone.Approved
RemoxiprideThe risk or severity of adverse effects can be increased when Iloperidone is combined with Remoxipride.Approved, Withdrawn
RepaglinideThe therapeutic efficacy of Repaglinide can be decreased when used in combination with Iloperidone.Approved, Investigational
ReproterolIloperidone may decrease the vasoconstricting activities of Reproterol.Investigational
ReserpineThe risk or severity of adverse effects can be increased when Reserpine is combined with Iloperidone.Approved, Investigational
RifabutinThe metabolism of Iloperidone can be increased when combined with Rifabutin.Approved, Investigational
RifampicinThe metabolism of Iloperidone can be increased when combined with Rifampicin.Approved
RifapentineThe metabolism of Iloperidone can be increased when combined with Rifapentine.Approved, Investigational
RilmenidineIloperidone may decrease the vasoconstricting activities of Rilmenidine.Approved, Investigational
RilpivirineThe serum concentration of Rilpivirine can be increased when it is combined with Iloperidone.Approved
RimiterolIloperidone may decrease the vasoconstricting activities of Rimiterol.Experimental
RisperidoneRisperidone may increase the antihypertensive activities of Iloperidone.Approved, Investigational
RitanserinThe risk or severity of adverse effects can be increased when Iloperidone is combined with Ritanserin.Investigational
RitobegronIloperidone may decrease the stimulatory activities of Ritobegron.Investigational
RitodrineIloperidone may decrease the vasoconstricting activities of Ritodrine.Approved, Investigational
RitonavirThe serum concentration of the active metabolites of Iloperidone can be increased when Iloperidone is used in combination with Ritonavir.Approved, Investigational
RizatriptanThe risk or severity of adverse effects can be increased when Rizatriptan is combined with Iloperidone.Approved
RolapitantThe metabolism of Iloperidone can be decreased when combined with Rolapitant.Approved, Investigational
RomifidineThe risk or severity of adverse effects can be increased when Iloperidone is combined with Romifidine.Vet Approved
RopiniroleIloperidone may increase the sedative activities of Ropinirole.Approved, Investigational
RopivacaineThe risk or severity of adverse effects can be increased when Iloperidone is combined with Ropivacaine.Approved
RosiglitazoneThe therapeutic efficacy of Rosiglitazone can be decreased when used in combination with Iloperidone.Approved, Investigational
RosuvastatinThe serum concentration of Rosuvastatin can be increased when it is combined with Iloperidone.Approved
RotigotineIloperidone may increase the sedative activities of Rotigotine.Approved
RucaparibThe metabolism of Iloperidone can be decreased when combined with Rucaparib.Approved, Investigational
RufinamideThe risk or severity of adverse effects can be increased when Rufinamide is combined with Iloperidone.Approved
SalbutamolSalbutamol may increase the QTc-prolonging activities of Iloperidone.Approved, Vet Approved
SalmeterolSalmeterol may increase the QTc-prolonging activities of Iloperidone.Approved
SaquinavirThe serum concentration of the active metabolites of Iloperidone can be increased when Iloperidone is used in combination with Saquinavir.Approved, Investigational
SarilumabThe therapeutic efficacy of Iloperidone can be decreased when used in combination with Sarilumab.Approved, Investigational
SaxagliptinThe therapeutic efficacy of Saxagliptin can be decreased when used in combination with Iloperidone.Approved
ScopolamineThe risk or severity of adverse effects can be increased when Scopolamine is combined with Iloperidone.Approved, Investigational
SecobarbitalThe risk or severity of adverse effects can be increased when Secobarbital is combined with Iloperidone.Approved, Vet Approved
SelegilineThe risk or severity of adverse effects can be increased when Selegiline is combined with Iloperidone.Approved, Investigational, Vet Approved
SeletracetamThe risk or severity of hypotension can be increased when Iloperidone is combined with Seletracetam.Investigational
SepranoloneThe risk or severity of adverse effects can be increased when Iloperidone is combined with Sepranolone.Investigational
SertindoleThe risk or severity of adverse effects can be increased when Iloperidone is combined with Sertindole.Approved, Investigational, Withdrawn
SertralineSertraline may increase the QTc-prolonging activities of Iloperidone.Approved
SevofluraneSevoflurane may increase the QTc-prolonging activities of Iloperidone.Approved, Vet Approved
SildenafilSildenafil may increase the hypotensive activities of Iloperidone.Approved, Investigational
SilodosinSilodosin may increase the antihypertensive activities of Iloperidone.Approved
SiltuximabThe serum concentration of Iloperidone can be decreased when it is combined with Siltuximab.Approved, Investigational
SimeprevirThe serum concentration of Iloperidone can be increased when it is combined with Simeprevir.Approved
SimvastatinThe serum concentration of Simvastatin can be increased when it is combined with Iloperidone.Approved
SitagliptinThe therapeutic efficacy of Sitagliptin can be decreased when used in combination with Iloperidone.Approved, Investigational
Sodium oxybateSodium oxybate may increase the central nervous system depressant (CNS depressant) activities of Iloperidone.Approved
SolabegronIloperidone may decrease the vasoconstricting activities of Solabegron.Investigational
SolifenacinSolifenacin may increase the QTc-prolonging activities of Iloperidone.Approved
SorafenibSorafenib may increase the QTc-prolonging activities of Iloperidone.Approved, Investigational
SotagliflozinThe therapeutic efficacy of Sotagliflozin can be decreased when used in combination with Iloperidone.Investigational
SotalolThe risk or severity of QTc prolongation can be increased when Sotalol is combined with Iloperidone.Approved
St. John's WortThe serum concentration of Iloperidone can be decreased when it is combined with St. John's Wort.Approved, Investigational, Nutraceutical
StiripentolThe serum concentration of Iloperidone can be increased when it is combined with Stiripentol.Approved
SufentanilThe risk or severity of adverse effects can be increased when Sufentanil is combined with Iloperidone.Approved, Investigational
SulfamethoxazoleSulfamethoxazole may increase the QTc-prolonging activities of Iloperidone.Approved
SulfisoxazoleSulfisoxazole may increase the QTc-prolonging activities of Iloperidone.Approved, Vet Approved
SulodexideThe therapeutic efficacy of Sulodexide can be decreased when used in combination with Iloperidone.Approved, Investigational
SulpirideIloperidone may increase the antipsychotic activities of Sulpiride.Approved, Investigational
SultoprideThe risk or severity of adverse effects can be increased when Iloperidone is combined with Sultopride.Experimental
SumatriptanThe risk or severity of adverse effects can be increased when Sumatriptan is combined with Iloperidone.Approved, Investigational
SunitinibSunitinib may increase the QTc-prolonging activities of Iloperidone.Approved, Investigational
SuvorexantIloperidone may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.Approved, Investigational
SynephrineIloperidone may decrease the vasoconstricting activities of Synephrine.Experimental
TadalafilTadalafil may increase the hypotensive activities of Iloperidone.Approved, Investigational
TalinololTalinolol may increase the orthostatic hypotensive activities of Iloperidone.Investigational
TamoxifenTamoxifen may increase the QTc-prolonging activities of Iloperidone.Approved
TamsulosinTamsulosin may increase the antihypertensive activities of Iloperidone.Approved, Investigational
TandospironeThe risk or severity of adverse effects can be increased when Iloperidone is combined with Tandospirone.Investigational
TapentadolTapentadol may increase the central nervous system depressant (CNS depressant) activities of Iloperidone.Approved
TasimelteonThe risk or severity of adverse effects can be increased when Iloperidone is combined with Tasimelteon.Approved, Investigational
Tedizolid PhosphateThe risk or severity of adverse effects can be increased when Tedizolid Phosphate is combined with Iloperidone.Approved
TelaprevirThe serum concentration of the active metabolites of Iloperidone can be increased when Iloperidone is used in combination with Telaprevir.Approved, Withdrawn
TelavancinTelavancin may increase the QTc-prolonging activities of Iloperidone.Approved
TelithromycinThe serum concentration of the active metabolites of Iloperidone can be increased when Iloperidone is used in combination with Telithromycin.Approved
TemazepamThe risk or severity of adverse effects can be increased when Temazepam is combined with Iloperidone.Approved, Investigational
Tenofovir disoproxilThe metabolism of Iloperidone can be decreased when combined with Tenofovir disoproxil.Approved, Investigational
TerazosinTerazosin may increase the antihypertensive activities of Iloperidone.Approved
TerbinafineThe serum concentration of the active metabolites of Iloperidone can be increased when Iloperidone is used in combination with Terbinafine.Approved, Investigational, Vet Approved
TerbutalineTerbutaline may increase the QTc-prolonging activities of Iloperidone.Approved
TergurideThe risk or severity of adverse effects can be increased when Terguride is combined with Iloperidone.Experimental
TeriflunomideThe serum concentration of Iloperidone can be decreased when it is combined with Teriflunomide.Approved
TerodilineThe risk or severity of hypotension can be increased when Iloperidone is combined with Terodiline.Experimental
TertatololTertatolol may increase the orthostatic hypotensive activities of Iloperidone.Experimental
TetrabenazineThe risk or severity of adverse effects can be increased when Tetrabenazine is combined with Iloperidone.Approved, Investigational
TetracaineThe risk or severity of adverse effects can be increased when Iloperidone is combined with Tetracaine.Approved, Vet Approved
TetrahydropalmatineThe risk or severity of adverse effects can be increased when Iloperidone is combined with Tetrahydropalmatine.Investigational
TetrodotoxinThe risk or severity of adverse effects can be increased when Iloperidone is combined with Tetrodotoxin.Investigational
TetryzolineIloperidone may decrease the vasoconstricting activities of Tetryzoline.Approved
ThalidomideIloperidone may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.Approved, Investigational, Withdrawn
TheophyllineTheophylline may increase the hypotensive activities of Iloperidone.Approved
ThiamylalThe risk or severity of adverse effects can be increased when Iloperidone is combined with Thiamylal.Approved, Vet Approved
ThiopentalThe risk or severity of adverse effects can be increased when Iloperidone is combined with Thiopental.Approved, Vet Approved
ThioproperazineThioproperazine may increase the antihypertensive activities of Iloperidone.Approved
ThioridazineThe serum concentration of the active metabolites of Iloperidone can be increased when Iloperidone is used in combination with Thioridazine.Approved, Withdrawn
ThiothixeneThiothixene may increase the QTc-prolonging activities of Iloperidone.Approved
TiagabineThe risk or severity of adverse effects can be increased when Tiagabine is combined with Iloperidone.Approved, Investigational
TiaprideThe risk or severity of adverse effects can be increased when Iloperidone is combined with Tiapride.Approved, Investigational
TiclopidineThe metabolism of Iloperidone can be decreased when combined with Ticlopidine.Approved
TiletamineThe risk or severity of adverse effects can be increased when Iloperidone is combined with Tiletamine.Vet Approved
TilidineThe risk or severity of adverse effects can be increased when Iloperidone is combined with Tilidine.Experimental
TimololTimolol may increase the orthostatic hypotensive activities of Iloperidone.Approved
TipranavirThe serum concentration of the active metabolites of Iloperidone can be increased when Iloperidone is used in combination with Tipranavir.Approved, Investigational
TizanidineTizanidine may increase the QTc-prolonging activities of Iloperidone.Approved, Investigational
TocilizumabThe serum concentration of Iloperidone can be decreased when it is combined with Tocilizumab.Approved
TolazamideThe therapeutic efficacy of Tolazamide can be decreased when used in combination with Iloperidone.Approved, Investigational
TolazolineTolazoline may increase the antihypertensive activities of Iloperidone.Approved, Vet Approved
TolbutamideThe therapeutic efficacy of Tolbutamide can be decreased when used in combination with Iloperidone.Approved, Investigational
TolcaponeThe risk or severity of adverse effects can be increased when Tolcapone is combined with Iloperidone.Approved, Withdrawn
Tolfenamic AcidThe risk or severity of hypotension can be increased when Iloperidone is combined with Tolfenamic Acid.Approved, Investigational
TolterodineTolterodine may increase the QTc-prolonging activities of Iloperidone.Approved, Investigational
TolvaptanThe serum concentration of Tolvaptan can be increased when it is combined with Iloperidone.Approved
TopiramateThe risk or severity of adverse effects can be increased when Topiramate is combined with Iloperidone.Approved
ToremifeneThe risk or severity of QTc prolongation can be increased when Toremifene is combined with Iloperidone.Approved, Investigational
TramadolThe risk or severity of adverse effects can be increased when Tramadol is combined with Iloperidone.Approved, Investigational
TranilastThe risk or severity of hypotension can be increased when Iloperidone is combined with Tranilast.Approved, Investigational
TranylcypromineThe metabolism of Iloperidone can be decreased when combined with Tranylcypromine.Approved, Investigational
TrazodoneTrazodone may increase the antihypertensive activities of Iloperidone.Approved, Investigational
TreprostinilTreprostinil may increase the QTc-prolonging activities of Iloperidone.Approved, Investigational
TretoquinolIloperidone may decrease the vasoconstricting activities of Tretoquinol.Experimental
TriazolamThe risk or severity of adverse effects can be increased when Triazolam is combined with Iloperidone.Approved, Investigational
Tricaine methanesulfonateThe risk or severity of adverse effects can be increased when Iloperidone is combined with Tricaine methanesulfonate.Vet Approved
TrichloroethyleneThe risk or severity of adverse effects can be increased when Iloperidone is combined with Trichloroethylene.Approved
TrifluoperazineTrifluoperazine may increase the antihypertensive activities of Iloperidone.Approved, Investigational
TrifluperidolThe risk or severity of adverse effects can be increased when Iloperidone is combined with Trifluperidol.Experimental
TriflupromazineThe risk or severity of adverse effects can be increased when Iloperidone is combined with Triflupromazine.Approved, Vet Approved
TrimazosinTrimazosin may increase the antihypertensive activities of Iloperidone.Experimental
TrimebutineThe risk or severity of hypotension can be increased when Iloperidone is combined with Trimebutine.Approved
TrimethadioneThe risk or severity of hypotension can be increased when Iloperidone is combined with Trimethadione.Approved
TrimethoprimTrimethoprim may increase the QTc-prolonging activities of Iloperidone.Approved, Vet Approved
TrimipramineTrimipramine may increase the antihypertensive activities of Iloperidone.Approved
TriprolidineThe risk or severity of adverse effects can be increased when Triprolidine is combined with Iloperidone.Approved
TriptorelinTriptorelin may increase the QTc-prolonging activities of Iloperidone.Approved, Vet Approved
TroglitazoneThe therapeutic efficacy of Troglitazone can be decreased when used in combination with Iloperidone.Investigational, Withdrawn
TulobuterolIloperidone may decrease the vasoconstricting activities of Tulobuterol.Investigational
UdenafilUdenafil may increase the hypotensive activities of Iloperidone.Approved, Investigational
UrapidilUrapidil may increase the antihypertensive activities of Iloperidone.Investigational
Valproic AcidThe risk or severity of adverse effects can be increased when Iloperidone is combined with Valproic Acid.Approved, Investigational
VandetanibThe risk or severity of QTc prolongation can be increased when Iloperidone is combined with Vandetanib.Approved
VardenafilVardenafil may increase the QTc-prolonging activities of Iloperidone.Approved
VemurafenibThe risk or severity of QTc prolongation can be increased when Vemurafenib is combined with Iloperidone.Approved
VenlafaxineVenlafaxine may increase the QTc-prolonging activities of Iloperidone.Approved
VeraliprideThe risk or severity of adverse effects can be increased when Iloperidone is combined with Veralipride.Experimental
VerapamilIloperidone may increase the antihypertensive activities of Verapamil.Approved
VigabatrinThe risk or severity of adverse effects can be increased when Vigabatrin is combined with Iloperidone.Approved
VilanterolVilanterol may increase the QTc-prolonging activities of Iloperidone.Approved
VilazodoneThe risk or severity of adverse effects can be increased when Vilazodone is combined with Iloperidone.Approved
VildagliptinThe therapeutic efficacy of Vildagliptin can be decreased when used in combination with Iloperidone.Approved, Investigational
VinpocetineThe risk or severity of hypotension can be increased when Iloperidone is combined with Vinpocetine.Investigational
Vinyl etherThe risk or severity of adverse effects can be increased when Iloperidone is combined with Vinyl ether.Experimental
VogliboseThe therapeutic efficacy of Voglibose can be decreased when used in combination with Iloperidone.Approved, Investigational
VoriconazoleThe serum concentration of the active metabolites of Iloperidone can be increased when Iloperidone is used in combination with Voriconazole.Approved, Investigational
VorinostatVorinostat may increase the QTc-prolonging activities of Iloperidone.Approved, Investigational
VortioxetineThe risk or severity of adverse effects can be increased when Vortioxetine is combined with Iloperidone.Approved, Investigational
WIN 55212-2The risk or severity of hypotension can be increased when Iloperidone is combined with WIN 55212-2.Experimental
XamoterolIloperidone may decrease the vasoconstricting activities of Xamoterol.Experimental
XenonThe risk or severity of adverse effects can be increased when Iloperidone is combined with Xenon.Experimental
XylazineThe risk or severity of adverse effects can be increased when Iloperidone is combined with Xylazine.Vet Approved
XylometazolineIloperidone may decrease the vasoconstricting activities of Xylometazoline.Approved, Investigational
ZaleplonThe risk or severity of adverse effects can be increased when Zaleplon is combined with Iloperidone.Approved, Illicit, Investigational
ZiconotideThe risk or severity of adverse effects can be increased when Iloperidone is combined with Ziconotide.Approved
ZimelidineThe risk or severity of adverse effects can be increased when Iloperidone is combined with Zimelidine.Withdrawn
ZiprasidoneThe risk or severity of QTc prolongation can be increased when Ziprasidone is combined with Iloperidone.Approved
ZolazepamThe risk or severity of adverse effects can be increased when Iloperidone is combined with Zolazepam.Vet Approved
ZolmitriptanThe risk or severity of adverse effects can be increased when Zolmitriptan is combined with Iloperidone.Approved, Investigational
ZolpidemIloperidone may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.Approved
ZonisamideThe risk or severity of adverse effects can be increased when Zonisamide is combined with Iloperidone.Approved, Investigational
ZopicloneThe risk or severity of adverse effects can be increased when Zopiclone is combined with Iloperidone.Approved
ZotepineThe risk or severity of adverse effects can be increased when Iloperidone is combined with Zotepine.Approved, Investigational, Withdrawn
ZucapsaicinThe metabolism of Iloperidone can be decreased when combined with Zucapsaicin.Approved, Investigational
ZuclopenthixolThe risk or severity of QTc prolongation can be increased when Zuclopenthixol is combined with Iloperidone.Approved, Investigational
Food Interactions
  • Administration of iloperidone with a standard high-fat meal did not significantly affect the Cmax or AUC of iloperidone, P88, or P95, but delayed Tmax by 1 hour for iloperidone, 2 hours for P88 and 6 hours for P95.
  • Can be taken with or without meals

References

Synthesis Reference
US5364866
General References
  1. Strupczewski JT, Bordeau KJ, Chiang Y, Glamkowski EJ, Conway PG, Corbett R, Hartman HB, Szewczak MR, Wilmot CA, Helsley GC: 3-[[(Aryloxy)alkyl]piperidinyl]-1,2-benzisoxazoles as D2/5-HT2 antagonists with potential atypical antipsychotic activity: antipsychotic profile of iloperidone (HP 873). J Med Chem. 1995 Mar 31;38(7):1119-31. [PubMed:7707315]
  2. Kongsamut S, Roehr JE, Cai J, Hartman HB, Weissensee P, Kerman LL, Tang L, Sandrasagra A: Iloperidone binding to human and rat dopamine and 5-HT receptors. Eur J Pharmacol. 1996 Dec 19;317(2-3):417-23. [PubMed:8997630]
  3. Hesselink JM: Iloperidone (Novartis). IDrugs. 2002 Jan;5(1):84-90. [PubMed:12861482]
  4. Hesselink JM: Iloperidone (Hoechst Marion Roussel Inc). IDrugs. 1999 Jun;2(6):584-90. [PubMed:16127622]
  5. Szewczak MR, Corbett R, Rush DK, Wilmot CA, Conway PG, Strupczewski JT, Cornfeldt M: The pharmacological profile of iloperidone, a novel atypical antipsychotic agent. J Pharmacol Exp Ther. 1995 Sep;274(3):1404-13. [PubMed:7562515]
  6. Bobo WV: Asenapine, iloperidone and lurasidone: critical appraisal of the most recently approved pharmacotherapies for schizophrenia in adults. Expert Rev Clin Pharmacol. 2013 Jan;6(1):61-91. doi: 10.1586/ecp.12.70. [PubMed:23272794]
  7. Citrome L: Iloperidone: chemistry, pharmacodynamics, pharmacokinetics and metabolism, clinical efficacy, safety and tolerability, regulatory affairs, and an opinion. Expert Opin Drug Metab Toxicol. 2010 Dec;6(12):1551-64. doi: 10.1517/17425255.2010.531259. Epub 2010 Nov 1. [PubMed:21034370]
External Links
KEGG Drug
D02666
PubChem Compound
71360
PubChem Substance
175426913
ChemSpider
64459
BindingDB
50034043
ChEBI
65173
ChEMBL
CHEMBL14376
PharmGKB
PA161199368
RxList
RxList Drug Page
Drugs.com
Drugs.com Drug Page
Wikipedia
Iloperidone
ATC Codes
N05AX14 — Iloperidone
FDA label
Download (352 KB)
MSDS
Download (480 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
1Active Not RecruitingTreatmentBioequivalence1
1CompletedNot AvailableHepatic Impairment1
1CompletedTreatmentSafety and Tolerability of Iloperidone1
1, 2CompletedTreatmentSchizophrenic Disorders1
2CompletedTreatmentEfficacy / Iloperidone / Schizophrenic Disorders1
2CompletedTreatmentPost Traumatic Stress Disorder (PTSD)1
3CompletedTreatmentSchizophrenic Disorders2
3RecruitingTreatmentSchizophrenic Disorders1
4CompletedTreatmentBipolar Disorder (BD)1
4CompletedTreatmentHealthy Volunteers1
4CompletedTreatmentMajor Depressive Disorder (MDD)1
4CompletedTreatmentPsychotic Disorder NOS1
4CompletedTreatmentSchizophrenic Disorders1
4TerminatedTreatmentSchizoaffective Disorders / Schizophrenic Disorders1
Not AvailableActive Not RecruitingNot AvailableSchizophrenic Disorders1
Not AvailableCompletedNot AvailableBipolar Disorder (BD)1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
FormRouteStrength
KitOral
TabletOral1 mg/1
TabletOral10 mg/1
TabletOral12 mg/1
TabletOral2 mg/1
TabletOral4 mg/1
TabletOral6 mg/1
TabletOral8 mg/1
Prices
Not Available
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
USRE39198No1996-11-152016-11-15Us
US8586610No2007-11-022027-11-02Us
US9074255No2010-12-172030-12-17Us
US9072742No2011-01-162031-01-16Us
US9074256No2011-02-102031-02-10Us
US9157121No2010-04-052030-04-05Us
US9138432No2005-09-302025-09-30Us
US8999638No2010-10-282030-10-28Us
US9074254No2011-12-282031-12-28Us
US8652776No2010-08-312030-08-31Us

Properties

State
Solid
Experimental Properties
PropertyValueSource
water solubilityInsoluble FDA label
Predicted Properties
PropertyValueSource
Water Solubility0.0304 mg/mLALOGPS
logP4.26ALOGPS
logP3.22ChemAxon
logS-4.2ALOGPS
pKa (Strongest Acidic)16.14ChemAxon
pKa (Strongest Basic)7.91ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count5ChemAxon
Hydrogen Donor Count0ChemAxon
Polar Surface Area64.8 Å2ChemAxon
Rotatable Bond Count8ChemAxon
Refractivity116.65 m3·mol-1ChemAxon
Polarizability46.51 Å3ChemAxon
Number of Rings4ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleYesChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+1.0
Blood Brain Barrier+0.9848
Caco-2 permeable+0.5513
P-glycoprotein substrateSubstrate0.6668
P-glycoprotein inhibitor IInhibitor0.8242
P-glycoprotein inhibitor IIInhibitor0.9268
Renal organic cation transporterInhibitor0.5726
CYP450 2C9 substrateNon-substrate0.9051
CYP450 2D6 substrateSubstrate0.892
CYP450 3A4 substrateSubstrate0.7409
CYP450 1A2 substrateNon-inhibitor0.6111
CYP450 2C9 inhibitorNon-inhibitor0.5061
CYP450 2D6 inhibitorNon-inhibitor0.886
CYP450 2C19 inhibitorInhibitor0.6257
CYP450 3A4 inhibitorInhibitor0.6777
CYP450 inhibitory promiscuityHigh CYP Inhibitory Promiscuity0.9008
Ames testNon AMES toxic0.6314
CarcinogenicityNon-carcinogens0.8699
BiodegradationNot ready biodegradable1.0
Rat acute toxicity2.7862 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.6563
hERG inhibition (predictor II)Inhibitor0.7945
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available
MS/MS Spectrum - , positiveLC-MS/MSsplash10-0059-1591700000-642ca68996469c31b6b8

Taxonomy

Description
This compound belongs to the class of organic compounds known as alkyl-phenylketones. These are aromatic compounds containing a ketone substituted by one alkyl group, and a phenyl group.
Kingdom
Organic compounds
Super Class
Organic oxygen compounds
Class
Organooxygen compounds
Sub Class
Carbonyl compounds
Direct Parent
Alkyl-phenylketones
Alternative Parents
Acetophenones / Benzisoxazoles / Phenoxy compounds / Anisoles / Methoxybenzenes / Benzoyl derivatives / Aryl alkyl ketones / Alkyl aryl ethers / Aralkylamines / Piperidines
show 10 more
Substituents
Alkyl-phenylketone / Acetophenone / Benzisoxazole / Phenoxy compound / Anisole / Benzoyl / Phenol ether / Aryl alkyl ketone / Methoxybenzene / Alkyl aryl ether
show 24 more
Molecular Framework
Aromatic heteropolycyclic compounds
External Descriptors
piperidines, organofluorine compound, tertiary amino compound, aromatic ether, methyl ketone, aromatic ketone, monoamine, 1,2-benzoxazoles (CHEBI:65173)

Targets

Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Antagonist
General Function
Virus receptor activity
Specific Function
G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for various drugs and psychoactive substances, including mescaline, psilocybin, 1-(2,5-dimethoxy-4-iodop...
Gene Name
HTR2A
Uniprot ID
P28223
Uniprot Name
5-hydroxytryptamine receptor 2A
Molecular Weight
52602.58 Da
References
  1. Kongsamut S, Roehr JE, Cai J, Hartman HB, Weissensee P, Kerman LL, Tang L, Sandrasagra A: Iloperidone binding to human and rat dopamine and 5-HT receptors. Eur J Pharmacol. 1996 Dec 19;317(2-3):417-23. [PubMed:8997630]
  2. Hesselink JM: Iloperidone (Novartis). IDrugs. 2002 Jan;5(1):84-90. [PubMed:12861482]
Details
2. D(2) dopamine receptor
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Antagonist
General Function
Potassium channel regulator activity
Specific Function
Dopamine receptor whose activity is mediated by G proteins which inhibit adenylyl cyclase.
Gene Name
DRD2
Uniprot ID
P14416
Uniprot Name
D(2) dopamine receptor
Molecular Weight
50618.91 Da
References
  1. Kongsamut S, Roehr JE, Cai J, Hartman HB, Weissensee P, Kerman LL, Tang L, Sandrasagra A: Iloperidone binding to human and rat dopamine and 5-HT receptors. Eur J Pharmacol. 1996 Dec 19;317(2-3):417-23. [PubMed:8997630]
  2. Hesselink JM: Iloperidone (Novartis). IDrugs. 2002 Jan;5(1):84-90. [PubMed:12861482]
Details
3. D(1A) dopamine receptor
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Antagonist
General Function
G-protein coupled amine receptor activity
Specific Function
Dopamine receptor whose activity is mediated by G proteins which activate adenylyl cyclase.
Gene Name
DRD1
Uniprot ID
P21728
Uniprot Name
D(1A) dopamine receptor
Molecular Weight
49292.765 Da
References
  1. Bobo WV: Asenapine, iloperidone and lurasidone: critical appraisal of the most recently approved pharmacotherapies for schizophrenia in adults. Expert Rev Clin Pharmacol. 2013 Jan;6(1):61-91. doi: 10.1586/ecp.12.70. [PubMed:23272794]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Antagonist
General Function
G-protein coupled amine receptor activity
Specific Function
Dopamine receptor whose activity is mediated by G proteins which inhibit adenylyl cyclase. Promotes cell proliferation.
Gene Name
DRD3
Uniprot ID
P35462
Uniprot Name
D(3) dopamine receptor
Molecular Weight
44224.335 Da
References
  1. George M, Amrutheshwar R, Rajkumar RP, Kattimani S, Dkhar SA: Newer antipsychotics and upcoming molecules for schizophrenia. Eur J Clin Pharmacol. 2013 Aug;69(8):1497-509. doi: 10.1007/s00228-013-1498-4. Epub 2013 Apr 2. [PubMed:23545936]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Antagonist
General Function
Sh3 domain binding
Specific Function
Dopamine receptor responsible for neuronal signaling in the mesolimbic system of the brain, an area of the brain that regulates emotion and complex behavior. Its activity is mediated by G proteins ...
Gene Name
DRD4
Uniprot ID
P21917
Uniprot Name
D(4) dopamine receptor
Molecular Weight
48359.86 Da
References
  1. Bobo WV: Asenapine, iloperidone and lurasidone: critical appraisal of the most recently approved pharmacotherapies for schizophrenia in adults. Expert Rev Clin Pharmacol. 2013 Jan;6(1):61-91. doi: 10.1586/ecp.12.70. [PubMed:23272794]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Antagonist
General Function
Serotonin receptor activity
Specific Function
G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for various drugs and psychoactive substances. Ligand binding causes a conformation change that triggers...
Gene Name
HTR1A
Uniprot ID
P08908
Uniprot Name
5-hydroxytryptamine receptor 1A
Molecular Weight
46106.335 Da
References
  1. Bobo WV: Asenapine, iloperidone and lurasidone: critical appraisal of the most recently approved pharmacotherapies for schizophrenia in adults. Expert Rev Clin Pharmacol. 2013 Jan;6(1):61-91. doi: 10.1586/ecp.12.70. [PubMed:23272794]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Antagonist
General Function
Serotonin receptor activity
Specific Function
This is one of the several different receptors for 5-hydroxytryptamine (serotonin), a biogenic hormone that functions as a neurotransmitter, a hormone, and a mitogen. The activity of this receptor ...
Gene Name
HTR6
Uniprot ID
P50406
Uniprot Name
5-hydroxytryptamine receptor 6
Molecular Weight
46953.625 Da
References
  1. Bobo WV: Asenapine, iloperidone and lurasidone: critical appraisal of the most recently approved pharmacotherapies for schizophrenia in adults. Expert Rev Clin Pharmacol. 2013 Jan;6(1):61-91. doi: 10.1586/ecp.12.70. [PubMed:23272794]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Antagonist
General Function
Serotonin receptor activity
Specific Function
This is one of the several different receptors for 5-hydroxytryptamine (serotonin), a biogenic hormone that functions as a neurotransmitter, a hormone, and a mitogen. The activity of this receptor ...
Gene Name
HTR7
Uniprot ID
P34969
Uniprot Name
5-hydroxytryptamine receptor 7
Molecular Weight
53554.43 Da
References
  1. Bobo WV: Asenapine, iloperidone and lurasidone: critical appraisal of the most recently approved pharmacotherapies for schizophrenia in adults. Expert Rev Clin Pharmacol. 2013 Jan;6(1):61-91. doi: 10.1586/ecp.12.70. [PubMed:23272794]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Antagonist
General Function
Protein heterodimerization activity
Specific Function
This alpha-adrenergic receptor mediates its action by association with G proteins that activate a phosphatidylinositol-calcium second messenger system. Its effect is mediated by G(q) and G(11) prot...
Gene Name
ADRA1A
Uniprot ID
P35348
Uniprot Name
Alpha-1A adrenergic receptor
Molecular Weight
51486.005 Da
References
  1. George M, Amrutheshwar R, Rajkumar RP, Kattimani S, Dkhar SA: Newer antipsychotics and upcoming molecules for schizophrenia. Eur J Clin Pharmacol. 2013 Aug;69(8):1497-509. doi: 10.1007/s00228-013-1498-4. Epub 2013 Apr 2. [PubMed:23545936]
Details
10. Histamine H1 receptor
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Antagonist
General Function
Histamine receptor activity
Specific Function
In peripheral tissues, the H1 subclass of histamine receptors mediates the contraction of smooth muscles, increase in capillary permeability due to contraction of terminal venules, and catecholamin...
Gene Name
HRH1
Uniprot ID
P35367
Uniprot Name
Histamine H1 receptor
Molecular Weight
55783.61 Da
References
  1. Bobo WV: Asenapine, iloperidone and lurasidone: critical appraisal of the most recently approved pharmacotherapies for schizophrenia in adults. Expert Rev Clin Pharmacol. 2013 Jan;6(1):61-91. doi: 10.1586/ecp.12.70. [PubMed:23272794]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Antagonist
General Function
Protein homodimerization activity
Specific Function
Alpha-2 adrenergic receptors mediate the catecholamine-induced inhibition of adenylate cyclase through the action of G proteins.
Gene Name
ADRA2C
Uniprot ID
P18825
Uniprot Name
Alpha-2C adrenergic receptor
Molecular Weight
49521.585 Da

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Steroid hydroxylase activity
Specific Function
Responsible for the metabolism of many drugs and environmental chemicals that it oxidizes. It is involved in the metabolism of drugs such as antiarrhythmics, adrenoceptor antagonists, and tricyclic...
Gene Name
CYP2D6
Uniprot ID
P10635
Uniprot Name
Cytochrome P450 2D6
Molecular Weight
55768.94 Da
References
  1. Mutlib AE, Klein JT: Application of liquid chromatography/mass spectrometry in accelerating the identification of human liver cytochrome P450 isoforms involved in the metabolism of iloperidone. J Pharmacol Exp Ther. 1998 Sep;286(3):1285-93. [PubMed:9732390]
  2. Citrome L: Iloperidone: chemistry, pharmacodynamics, pharmacokinetics and metabolism, clinical efficacy, safety and tolerability, regulatory affairs, and an opinion. Expert Opin Drug Metab Toxicol. 2010 Dec;6(12):1551-64. doi: 10.1517/17425255.2010.531259. Epub 2010 Nov 1. [PubMed:21034370]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Vitamin d3 25-hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation react...
Gene Name
CYP3A4
Uniprot ID
P08684
Uniprot Name
Cytochrome P450 3A4
Molecular Weight
57342.67 Da
References
  1. Mutlib AE, Klein JT: Application of liquid chromatography/mass spectrometry in accelerating the identification of human liver cytochrome P450 isoforms involved in the metabolism of iloperidone. J Pharmacol Exp Ther. 1998 Sep;286(3):1285-93. [PubMed:9732390]
  2. Citrome L: Iloperidone: chemistry, pharmacodynamics, pharmacokinetics and metabolism, clinical efficacy, safety and tolerability, regulatory affairs, and an opinion. Expert Opin Drug Metab Toxicol. 2010 Dec;6(12):1551-64. doi: 10.1517/17425255.2010.531259. Epub 2010 Nov 1. [PubMed:21034370]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Oxygen binding
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP3A5
Uniprot ID
P20815
Uniprot Name
Cytochrome P450 3A5
Molecular Weight
57108.065 Da
References
  1. Mutlib AE, Klein JT: Application of liquid chromatography/mass spectrometry in accelerating the identification of human liver cytochrome P450 isoforms involved in the metabolism of iloperidone. J Pharmacol Exp Ther. 1998 Sep;286(3):1285-93. [PubMed:9732390]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Oxygen binding
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP3A7
Uniprot ID
P24462
Uniprot Name
Cytochrome P450 3A7
Molecular Weight
57525.03 Da
References
  1. Mutlib AE, Klein JT: Application of liquid chromatography/mass spectrometry in accelerating the identification of human liver cytochrome P450 isoforms involved in the metabolism of iloperidone. J Pharmacol Exp Ther. 1998 Sep;286(3):1285-93. [PubMed:9732390]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Steroid hydroxylase activity
Specific Function
Metabolizes several precarcinogens, drugs, and solvents to reactive metabolites. Inactivates a number of drugs and xenobiotics and also bioactivates many xenobiotic substrates to their hepatotoxic ...
Gene Name
CYP2E1
Uniprot ID
P05181
Uniprot Name
Cytochrome P450 2E1
Molecular Weight
56848.42 Da
References
  1. Mutlib AE, Klein JT: Application of liquid chromatography/mass spectrometry in accelerating the identification of human liver cytochrome P450 isoforms involved in the metabolism of iloperidone. J Pharmacol Exp Ther. 1998 Sep;286(3):1285-93. [PubMed:9732390]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP1A2
Uniprot ID
P05177
Uniprot Name
Cytochrome P450 1A2
Molecular Weight
58293.76 Da
References
  1. Mutlib AE, Klein JT: Application of liquid chromatography/mass spectrometry in accelerating the identification of human liver cytochrome P450 isoforms involved in the metabolism of iloperidone. J Pharmacol Exp Ther. 1998 Sep;286(3):1285-93. [PubMed:9732390]

Drug created on October 21, 2007 16:23 / Updated on July 02, 2018 18:24